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Abstract
Medications for chronic obstructive pulmonary disease:
a historical non-interventional cohort study with validation
against RCT results
Kevin Wing ,1* Elizabeth Williamson ,2 James R Carpenter ,2
Lesley Wise ,1 Sebastian Schneeweiss ,3,4 Liam Smeeth ,1
Jennifer K Quint 5 and Ian Douglas 1
1Department of Non-communicable Disease Epidemiology, Faculty of Epidemiology and Population
Health, London School of Hygiene & Tropical Medicine, London, UK
2Department of Medical Statistics, Faculty of Epidemiology and Population Health, London School of
Hygiene & Tropical Medicine, London, UK
3Department of Epidemiology, Harvard Medical School, Boston, MA, USA
4Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and
Women’s Hospital, Boston, MA, USA
5National Heart and Lung Institute, Imperial College London, London, UK
*Corresponding author kevin.wing@lshtm.ac.uk
Background: Chronic obstructive pulmonary disease treatment is informed by randomised controlled
trial results, but it is unclear if these findings apply to people excluded from these trials. We used data
from the TORCH (TOwards a Revolution in COPD Health) randomised controlled trial to validate
non-interventional methods for assessing the clinical effectiveness of chronic obstructive pulmonary
disease treatment in the UK Clinical Practice Research Datalink, before applying these methods to the
analysis of people who would have been excluded from TORCH.
Objectives: To validate the use of non-interventional Clinical Practice Research Datalink data and
methods for estimating chronic obstructive pulmonary disease treatment effects against trial results,
and, using validated methods, to determine treatment effects in people who would have been excluded
from the TORCH trial.
Design: A historical non-interventional cohort design, including validation against randomised
controlled trial results.
Setting: The UK Clinical Practice Research Datalink.
Participants: People aged ≥ 18 years with chronic obstructive pulmonary disease registered in Clinical
Practice Research Datalink GOLD between January 2000 and January 2017. For objective 1, we
prepared a cohort that was analogous to the TORCH trial cohort by applying TORCH trial inclusion/
exclusion criteria followed by individual matching to TORCH trial participants. For objectives 2 and 3,
we prepared cohorts that were analogous to the TORCH trial that, nevertheless, would not have been
eligible for the TORCH trial because of age, asthma, comorbidity or mild disease.
Interventions: The long-acting beta-2 agonist and inhaled corticosteroid combination product Seretide
(GlaxoSmithKline plc) [i.e. fluticasone propionate plus salmeterol (FP-SAL)] compared with (1) no FP-SAL
exposure or (2) exposure to salmeterol (i.e. the long-acting beta-2 agonist) only.
Main outcome measures: Exacerbations, mortality, pneumonia and time to treatment change.
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Results: For objective 1, the exacerbation rate ratio was comparable to that in the TORCH trial for
FP-SAL compared with salmeterol (0.85, 95% confidence interval 0.74 to 0.97, vs. TORCH trial 0.88,
95% confidence interval 0.81 to 0.95), but not for FP-SAL compared with no FP-SAL (1.30, 95%
confidence interval 1.19 to 1.42, vs. TORCH trial 0.75, 95% confidence interval 0.69 to 0.81). Active
comparator results were also consistent with the TORCH trial for mortality (hazard ratio 0.93, 95%
confidence interval 0.65 to 1.32, vs. TORCH trial hazard ratio 0.93, 95% confidence interval 0.77 to
1.13) and pneumonia (risk ratio 1.39, 95% confidence interval 1.04 to 1.87, vs. TORCH trial risk ratio
1.47, 95% confidence interval 1.25 to 1.73). For objectives 2 and 3, active comparator results were
consistent with the TORCH trial for exacerbations, with the exception of people with milder chronic
obstructive pulmonary disease, in whom we observed a stronger protective association (risk ratio 0.56,
95% confidence interval 0.46 to 0.70, vs. TORCH trial risk ratio 0.85, 95% confidence interval 0.74
to 0.97). For the analysis of mortality, we saw a lack of association with being prescribed FP-SAL
(vs. being prescribed salmeterol), with the exception of those with prior asthma, for whom we
observed an increase in mortality (hazard ratio 1.49, 95% confidence interval 1.21 to 1.85, vs. TORCH
trial-analogous HR 0.93, 95% confidence interval 0.64 to 1.32).
Conclusions: Routinely collected electronic health record data can be used to successfully measure
chronic obstructive pulmonary disease treatment effects when comparing two treatments, but not
for comparisons between active treatment and no treatment. Analyses involving patients who would
have been excluded from trials mostly suggests that treatment effects for FP-SAL are similar to trial
effects, although further work is needed to characterise a small increased risk of death in those with
concomitant asthma.
Limitations: Some of our analyses had small numbers.
Future work: The differences in treatment effects that we found should be investigated further in
other data sets. Currently recommended chronic obstructive pulmonary disease inhaled combination
therapy (other than FP-SAL) should also be investigated using these methods.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 25, No. 51. See the NIHR Journals Library website for further project information.
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Chronic obstructive pulmonary disease affects 3 million people in the UK and is characterised bybreathing difficulties that get worse over time, with sudden acute symptoms (exacerbations),
possibly requiring hospitalisation. The evidence for use of medicines for treating chronic obstructive
pulmonary disease comes from randomised controlled trial results. Randomised controlled trials
generally include younger people with severe disease who do not have any other illnesses apart from
chronic obstructive pulmonary disease, meaning that the effectiveness of these trials in all people with
chronic obstructive pulmonary disease is unknown. Very large databases of anonymous electronic
health records captured during NHS consultations can be used to study patients excluded from trials.
However, confidence in results from studies using these data can be low because of fears of unaccounted
bias, as patients are not randomised to treatment. In this project, we selected a group of patients from a
very large electronic health record database called the Clinical Practice Research Datalink who were very
similar to participants in a well-known large chronic obstructive pulmonary disease randomised controlled
trial [the TORCH (TOwards a Revolution in COPD Health) trial]. When we analysed data from these
patients, we found very similar results to the TORCH trial in relation to the reduction of exacerbations,
development of pneumonia and time until death, when comparing one chronic obstructive pulmonary
disease treatment with another. Having shown that our methods could be trusted to produce valid
results when comparing one chronic obstructive pulmonary disease treatment with another, we then
went on to analyse patients in the Clinical Practice Research Datalink who would have been excluded
from the TORCH trial for the following reasons: aged > 80 years, having asthma as well as chronic
obstructive pulmonary disease, or having only mild chronic obstructive pulmonary disease. For
exacerbations, we found that, for people with milder chronic obstructive pulmonary disease, one of the
treatments we studied seemed to work better than in the trial. For the analysis of mortality, we found
that, for people with asthma as well as chronic obstructive pulmonary disease, one of the treatments
seemed not to work so well, with more people dying. Future studies are needed in different populations
(such as in a database from another country) to confirm these results.
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Text in this summary is reproduced with permission from Wing K, Williamson E, Carpenter JR,Wise L, Schneeweiss S, Smeeth L, et al. Real-world effects of medications for chronic obstructive
pulmonary disease: protocol for a UK population-based non-interventional cohort study with validation
against randomised trial results. BMJ Open 2018;8:e019475. This is an Open Access article distributed
in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use, provided the original
work is properly cited. See: https://creativecommons.org/licenses/by/4.0/. The text below includes
minor additions and formatting changes to the original text.
Background
Chronic obstructive pulmonary disease affects 3 million people in the UK. The most common cause is
smoking, and patients exhibit airflow obstruction that is not fully reversible. The disease is progressive,
with declining lung function and worsening symptoms. Most troublesome are acute exacerbations
manifested as a sudden worsening of symptoms (e.g. severe coughing, shortness of breath and chest
congestion) that require urgent treatment and possibly hospitalisation. Although smoking cessation remains
the most effective intervention, the rate of exacerbation can be reduced by regular medication, such as
combination long-acting beta agonists and inhaled corticosteroids or long-acting muscarinic antagonists.
Chronic obstructive pulmonary disease treatment guidelines are largely informed by randomised
controlled trial results, but it is not clear if these findings apply to large patient populations that are
not studied in these trials. Fluticasone propionate plus salmeterol (FP-SAL) [Seretide (GlaxoSmithKline
plc)] is a long-acting beta agonist/inhaled corticosteroid combination and is one of the most widely
used chronic obstructive pulmonary disease treatments. It has been studied in large randomised
trials [e.g. the TORCH (TOwards a Revolution in COPD Health) trial], but the effects of treatment in
important patient groups who were not studied are unknown. Some patient groups were excluded
from trials (e.g. those aged > 80 years, those with concomitant asthma or those with substantial
comorbidity), whereas others are under-represented (e.g. people with mild chronic obstructive
pulmonary disease), meaning that conclusions about these groups are difficult to make.
Although the conduct of non-interventional studies (sometimes also referred to as ‘observational
studies’) to investigate possible drug harms is well established, the use of these studies to estimate
treatment effectiveness is in its infancy. Issues of treatment channelling and indication bias mean
that measuring the intended benefit of a treatment is beset with difficulties. Over the next few years,
we believe that we will see more non-interventional studies of drug effectiveness emerging because
of recent legislation that requires pharmaceutical companies to study the real-world effects of
medications; however, rigorous, validated methodology is needed to translate these complex data into
reliable evidence. For example, the availability of anonymised individual patient data from randomised
controlled trials provides the potential for ‘randomised controlled trial-analogous’ cohorts to be selected
from non-interventional data sources (by matching patient records from non-interventional data to
the randomised controlled trial patient records on key characteristics). If subsequent analysis of a
non-interventional randomised controlled trial-analogous cohort generates results that are similar to
those generated by the reference randomised controlled trial, one could be confident in the validity of
the results and in the non-interventional methods used to obtain these results in this setting.
In this study we used TORCH individual trial data to validate non-interventional methods for assessing
chronic obstructive pulmonary disease treatment effectiveness, before going on to apply these methods
to the analysis of treatment effectiveness within people excluded from, or under-represented in,
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the TORCH trial. Non-interventional data were obtained from the UK Clinical Practice Research
Datalink (linked to the Hospital Episodes Statistics database). The results generated could aid patients,
prescribers and policy-makers in deciding the most appropriate treatment for chronic obstructive
pulmonary disease for all types of patients. The approach used can also provide a template for
treatment effectiveness research using non-interventional data with inbuilt validation against a
randomised trial.
Aims and objectives
The aims of our study were as follows:
l to measure the association between treatments for chronic obstructive pulmonary disease and a
number of chronic obstructive pulmonary disease outcomes, including exacerbation rate, mortality,
pneumonia and time to treatment change, among patients not included in randomised clinical trials
for chronic obstructive pulmonary disease treatments
l to develop a methodological framework with inbuilt validation against randomised controlled trial
data for using non-interventional electronic health records to answer questions about drug
treatment effects (i.e. both benefits and risks).
Specific objectives were to:
l validate methods for measuring chronic obstructive pulmonary disease medication effectiveness in
electronic health record data by comparing with trial results
l use electronic health record data to measure chronic obstructive pulmonary disease medication
effectiveness in patients excluded from trials (most importantly, those aged > 80 years or those
with comorbidities)
l determine chronic obstructive pulmonary disease treatment effectiveness in an understudied
disease stage (i.e. mild chronic obstructive pulmonary disease).
Methods
We performed a historical cohort study (2000–17) of chronic obstructive pulmonary disease drug
treatment effects in the UK Clinical Practice Research Datalink. For objective 1 (i.e. validation of
methods against the TORCH trial), two control groups were selected from the Clinical Practice
Research Datalink by applying TORCH trial inclusion/exclusion criteria and 1 : 1 matching to individual
TORCH trial participants. Control group 1 included people with chronic obstructive pulmonary disease
not prescribed FP-SAL and control group 2 included people with chronic obstructive pulmonary
disease who were prescribed salmeterol only. FP-SAL-exposed groups were then selected from Clinical
Practice Research Datalink by propensity score matching to each control group. Outcomes studied
were chronic obstructive pulmonary disease exacerbations, death from any cause and pneumonia. For
objectives 2 and 3 (i.e. analyses of chronic obstructive pulmonary disease medication effectiveness in
patients excluded from trials or with an understudied disease stage), the validated methods for patient
selection and propensity score development from objective 1 were used to select and analyse the same
outcomes in cohorts of people with chronic obstructive pulmonary disease in the Clinical Practice
Research Datalink who would have been excluded from the TORCH trial because of age, comorbidities
or having mild chronic obstructive pulmonary disease (but who would have otherwise met the TORCH
trial criteria). For objectives 2 and 3, the control group was people with chronic obstructive pulmonary
disease who were prescribed salmeterol.
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Results
For the validation stage (i.e. objective 1), 2652 FP-SAL-exposed people were propensity score matched
to 2652 unexposed people, and 991 FP-SAL-exposed people were propensity score matched to
991 salmeterol-exposed people. Exacerbation rate ratio was comparable to the TORCH trial for
FP-SAL compared with salmeterol (0.85, 95% confidence interval 0.74 to 0.97, vs. TORCH trial 0.88,
95% confidence interval 0.81 to 0.95), but not for FP-SAL compared with no FP-SAL (1.30, 95% confidence
interval 1.19 to 1.42, vs. TORCH trial 0.75, 95% confidence interval 0.69 to 0.81). Active comparator
results were also consistent with the TORCH trial for mortality (hazard ratio 0.93, 95% confidence
interval 0.65 to 1.32, vs. TORCH trial hazard ratio 0.93, 95% confidence interval 0.77 to 1.13) and
pneumonia (risk ratio 1.39, 95% confidence interval 1.04 to 1.87, vs. TORCH trial risk ratio 1.47,
95% confidence interval 1.25 to 1.73). However, different result were obtained from the TORCH
trial for the FP-SAL-exposed compared with FP-SAL-unexposed analysis of mortality and pneumonia
(mortality hazard ratio 1.11, 95% confidence interval 0.95 to 1.26, vs. TORCH trial mortality hazard
ratio 0.83, 95% confidence interval 0.68 to 1.00; pneumonia risk ratio 1.14, 95% confidence interval
0.96 to 1.34, vs. TORCH trial pneumonia risk ratio 1.59, 95% confidence interval 1.35 to 1.88). Time to
treatment continuation differed from the TORCH trial for both the FP-SAL compared with salmeterol
and FP-SAL compared with no FP-SAL analyses (e.g. FP-SAL vs. SAL hazard ratio 0.23, 95% confidence
interval 0.20 to 0.27, vs. TORCH trial hazard ratio 0.89, 95% confidence interval 0.79 to 0.99).
For the over-80s cohort exacerbations analysis, we obtained a propensity score-matched rate ratio of 0.59
(95% confidence interval 0.36 to 0.95) and a propensity score-adjusted rate ratio of 0.83 (95% confidence
interval 0.60 to 1.14), which is consistent with the association measured in the TORCH trial-analogous
Clinical Practice Research Datalink population (0.85, 95% confidence interval 0.74 to 0.97). For the
mortality outcome, we obtained a propensity score-matched hazard ratio of 0.99 (95% confidence interval
0.56 to 1.74) and a propensity score-adjusted hazards ratio of 1.29 (95% confidence interval 0.84 to 2.00).
Again, this is consistent with the TORCH trial-analogous Clinical Practice Research Datalink result (0.93,
95% confidence interval 0.65 to 1.32). For the pneumonia analysis, we found no evidence for an increased
risk associated with FP-SAL, with a propensity score-matched rate ratio of 0.82 (95% confidence interval
0.44 to 1.53) and a propensity score-adjusted rate ratio of 0.88 (95% confidence interval 0.54 to 1.42).
For the analysis of exacerbations in the cohort of people with concomitant asthma, we found a
propensity score-matched rate ratio of 0.74 (95% confidence interval 0.62 to 0.89) and a propensity
score-adjusted rate ratio of 0.67 (95% confidence interval 0.59 to 0.78), which is consistent with the
association measured in the TORCH trial-analogous Clinical Practice Research Datalink population
(0.85, 95% confidence interval 0.74 to 0.97). For the mortality outcome, we obtained a propensity
score-matched hazard ratio of 1.49 (95% confidence interval 1.21 to 1.85) and propensity score-
adjusted hazards ratio of 1.20 (95% confidence interval 1.04 to 1.40), contrary to the null findings with
the TORCH trial-analogous Clinical Practice Research Datalink result (0.93, 95% confidence interval
0.65 to 1.32). For the pneumonia analysis, we found no evidence for an increased risk associated with
FP-SAL, with a propensity score-matched rate ratio of 1.09 (95% confidence interval 0.74 to 1.63) and
a propensity score-adjusted rate ratio of 1.04 (95% confidence interval 0.79 to 1.37).
For the people with mild chronic obstructive pulmonary disease, we found a propensity score-matched
rate ratio for exacerbations of 0.56 (95% confidence interval 0.46 to 0.70) and a propensity score-adjusted
rate ratio of 0.52 (95% confidence interval 0.45 to 0.61), which suggests a stronger protective association
than that measured in the TORCH trial-analogous Clinical Practice Research Datalink population (0.85,
95% confidence interval 0.74 to 0.97). Notably, however, the crude association in those with mild
chronic obstructive pulmonary disease was also strongly protective, unlike in the TORCH trial-analogous
population. For the mortality outcome, we obtained a propensity score-matched hazard ratio of
0.98 (95% confidence interval 0.67 to 1.45) and a propensity score-adjusted hazards ratio of 0.84
(95% confidence interval 0.66 to 1.08). Again, this is consistent with the TORCH trial-analogous Clinical
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Practice Research Datalink result (0.93, 95% confidence interval 0.65 to 1.32). For the pneumonia
analysis, we found no evidence for an increased risk associated with FP-SAL, with a propensity score-
matched rate ratio of 0.78 (95% confidence interval 0.45 to 1.35) and a propensity score-adjusted rate
ratio of 1.08 (95% confidence interval 0.74 to 1.57).
Conclusions
Our results suggest that routinely collected electronic health record data can be used to successfully
identify the expected beneficial and harmful effects of treatments for chronic obstructive pulmonary
disease when validating against results obtained from randomised trials. Importantly, successful
replication was possible only when comparing between two active treatments, and could not be
achieved for comparisons between active treatment and no treatment. These conclusions are specific
to investigations of the effects of chronic obstructive pulmonary disease medication and cannot be
assumed to replicate in other disease areas. In validating against the results of a large international
multicentre randomised trial, it was also clear that, in some instances, some patient characteristics
observed in a trial are not always observed in a single-country electronic health record setting. This
raises questions of possible trial result heterogeneity by geographic region, which should be considered
in future attempts to replicate trial findings in non-interventional data.
The step of directly comparing findings from non-interventional data with those from the trial provided
a methodological validation and template, allowing further work to focus on the types of patients
excluded from the original trials.
Analyses involving patients who would have been excluded from, or were under-represented in, chronic
obstructive pulmonary disease treatment trials mostly suggest that treatment effects for FP-SAL are
similar in patients aged > 80 years, those with mild chronic obstructive pulmonary disease and those
with both asthma and chronic obstructive pulmonary disease. However, some potential differences were
also suggested. For people with mild chronic obstructive pulmonary disease, the use of FP-SAL appears
to be more beneficial with respect to exacerbations than was seen in the TORCH trial-analogous
population. By contrast, we observed a small increased risk of mortality when comparing FP-SAL with
salmeterol in the group with both chronic obstructive pulmonary disease and asthma. These associations
should be interpreted with caution, and we recommend future studies to focus on further characterising
these associations.
Overall, we have demonstrated the utility of non-interventional data to investigate the expected
treatment effects of chronic obstructive pulmonary disease medications, in both trial-included and
trial-excluded patient groups. Analyses largely suggest that chronic obstructive pulmonary disease
treatment effects are consistent across different patient groups, but highlighted a small number of
possible differences that should be investigated further in other data sets. Unanswered questions
about the effectiveness of currently recommended chronic obstructive pulmonary disease inhaled
combination therapy (other than FP-SAL) in patients excluded from trials should also be investigated
using these methods, and further work on advanced technique (e.g. high-dimensional propensity
scores) could be performed to investigate whether or not placebo-controlled randomised controlled
trials can ever be replicated in this therapeutic area.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 51.
See the NIHR Journals Library website for further project information.
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Chapter 1 Introduction
Parts of this chapter have been reproduced with permission from Wing et al.1 This is an Open Accessarticle distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0)
license, which permits others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: https://creativecommons.org/licenses/by/4.0/. The text
below includes minor additions and formatting changes to the original text.
Background
Chronic obstructive pulmonary disease (COPD) affects 3 million people in the UK.2 The most common
cause is smoking, and patients exhibit airflow obstruction that is not fully reversible. The disease is
progressive, with declining lung function and a worsening of symptoms. Most troublesome are acute
exacerbations manifested as a sudden worsening of symptoms (e.g. severe coughing, shortness of
breath and chest congestion) that require urgent treatment and possibly hospitalisation. Although
smoking cessation remains the most effective intervention, the rate of exacerbation can be reduced by
regular medication, such as combination long-acting beta agonists (LABAs) and inhaled corticosteroids
(ICSs) or long-acting muscarinic antagonists (LAMAs).3,4
Chronic obstructive pulmonary disease treatment guidelines are largely informed by randomised
controlled trial (RCT) results,5 but it is not clear if these findings apply to the large patient populations
who are not studied in these trials. Fluticasone propionate plus salmeterol (FP-SAL) [seretide
(GlaxoSmithKline plc)] is a LABA/ICS combination and is one of the most widely used COPD
treatments. It was studied in large randomised trials [e.g. the TORCH (TOwards a Revolution in
COPD Health) trial],3 but the effects of treatment in important patient groups who were not studied
are unknown. Some patients were excluded from trials (e.g. those aged > 80 years, those with
concomitant asthma or those with substantial comorbidity), whereas others are under-represented
(e.g. people with mild COPD),3,6 meaning that conclusions about these groups are difficult to make.
Although the conduct of non-interventional studies (sometimes also referred to as ‘observational
studies’) to investigate possible drug harms is well established, the use of these studies to estimate
treatment effectiveness is in its infancy. Issues of treatment channelling and indication bias mean
that measuring the intended benefit of a treatment is beset with difficulties. Over the next few years,
we believe that we will see more non-interventional studies of drug effectiveness emerging because
of recent legislation that requires pharmaceutical companies to study the real-world effects of
medications;7,8 however, rigorous, validated methodology is needed to translate these complex data
into reliable evidence.
For example, the availability of anonymised individual patient data from RCTs provides the potential
for ‘RCT-analogous’ cohorts to be selected from non-interventional data sources (by first applying
the trial inclusion and exclusion criteria to a non-interventional data source and then matching patient
records from non-interventional data to the RCT patient records on key characteristics). Once a cohort
of patients has been selected from non-interventional data with very similar characteristics to the
original trial population, analysis can be performed of this cohort, looking at the same outcomes as the
trial, but applying statistical methods for analysing non-interventional data. If the results of analysing a
RCT-analogous cohort in this way are different from the trial results, this shows that issues with the
validity of the analysis remain, even after creating a non-interventional cohort that is highly comparable
to the trial. If, however, subsequent analysis of this non-interventional RCT-analogous cohort generates
results that are similar to those generated by the reference RCT, one could be confident in the validity
of the results and also in the non-interventional methods used to obtain these results in this setting.
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This would then provide confidence that if one applies similar analysis approaches to cohorts of patients
who were excluded from the trial but have been selected in a similar way to the trial (in terms of
inclusion and exclusion criteria but not trial matching, as the trial did not include these patients by design
so they would not be available for matching), then the results obtained are likely to be valid.
In this study, we used TORCH3 individual trial data to validate non-interventional methods for
assessing COPD treatment effectiveness, before going on to apply these methods to the analysis
of treatment effectiveness within people excluded from, or under-represented in, the TORCH trial.3
Non-interventional data were obtained from the UK Clinical Practice Research Datalink (CPRD)
[linked to the Hospital Episode Statistics (HES) database].9 The results generated could aid patients,
prescribers and policy-makers in deciding the most appropriate treatment for COPD for all types of
patients. The approach used can also provide a template for treatment effectiveness research using
non-interventional data with inbuilt validation against a randomised trial.
Aims and objectives
The aims of our study were as follows:
l to measure the association between treatments for COPD and a number of COPD outcomes,
including exacerbation rate, mortality, pneumonia and time to treatment change, among patients not
included in randomised clinical trials for COPD treatments
l to develop a methodological framework with inbuilt validation against RCT data for using non-
interventional electronic health records (EHRs) to answer questions about drug treatment effects
(i.e. both benefits and risks).
Specific objectives were to:
l validate methods for measuring COPD medication effectiveness in EHR data by comparing with
trial results
l use EHR data to measure COPD medication effectiveness in patients excluded from trials
(most importantly, those aged > 80 years or those with comorbidities)
l determine COPD treatment effectiveness in an understudied disease stage (i.e. mild COPD).
Figure 1 provides a high-level overview of the study approach, detailing each objective and data source
used. Figure 1 illustrates how existing RCT data were used in objective 1 to validate methods for
analysing COPD in routinely collected electronic data for application to unanswered questions in
objectives 2 and 3.
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FIGURE 1 Overview of the COPD real-world medicines effects study. A, Work performed by others prior to this study.
Of the total population of people with COPD, only a subset are included in RCTs of COPD treatments, based on the RCT
inclusion/exclusion criteria. The RCT generates results that inform clinical practice, and the anonymised raw data for the
study can be made available to other researchers via the Clinical Study Data Request website. For this study, the specific
COPD treatment RCT of interest is the TORCH trial,3 which investigated the effect of FP-SAL on COPD exacerbations.
B, Work performed as part of this study. Objective 1: a cohort of TORCH trial-analogous3 patients was selected from
the UK CPRD by matching people with COPD within CPRD to the records of people included in the trial. Analyses
of the effect of FP-SAL on COPD exacerbations were then performed on this TORCH-analogous3 CPRD cohort. The
result obtained were then compared with the TORCH trial3 itself, serving as a validation step, with comparable results
indicating that the data from the non-interventional (‘real-world’) CPRD source can reliably be used to study COPD
treatment effects. Objective 2: the validated analysis techniques used for objective 1 were used to study people
in CPRD who would not have been eligible for inclusion in a RCT because of their age and the presence of other
comorbidities, and for whom the effect of FP-SAL is currently unknown. Objective 3: the validated analysis techniques
were then used to study people with only mild COPD who have been under-represented in RCTs and for whom the
effect of COPD treatments is unclear. Reproduced with permission from Wing et al.1 This is an Open Access article
distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly
cited. See: https://creativecommons.org/licenses/by/4.0/. The figure includes minor additions and formatting changes to
the original.
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Study design
A historical cohort study, with validation against RCT results.
Ethics approval and research governance
Scientific approval was provided by the London School of Hygiene & Tropical Medicine Research Ethics
Committee (reference 11997) and the Independent Scientific Advisory Committee of the Medicines and
Healthcare products Regulatory Agency (protocol number 17_114R). CPRD data are already approved
via a National Research Ethics Committee for purely non-interventional research of this type. Approval
for use of the TORCH trial3 data was obtained from the Wellcome Trust (London, UK), the relevant
sponsor (GlaxoSmithKline plc, Brentford, UK) and an independent review panel.
Setting/data sources
Patient data used in this study were obtained from two different sources: the TORCH trial3 and the
UK CPRD (linked to HES data).
The TORCH trial3
The TORCH trial3 was a placebo-controlled randomised trial of combined inhaler FP-SAL for the treatment
of COPD, published in 2007. Patients were randomised to receive FP-SAL, fluticasone propionate (FP)
alone, salmeterol (SAL) alone or placebo, and the primary comparison of interest was between FP-SAL
and placebo.3 Key outcomes were expected benefits (with a primary outcome of decreased mortality
and additional outcome of a decrease in the rate of COPD exacerbations) and an expected harm due to
the immunosuppressive action of the corticosteroid FP (pneumonia). Although findings for the primary
end point of mortality were null, this was thought to be because of poor statistical power as a result of a
lower than anticipated mortality rate. Nonetheless, a lower rate of exacerbations was seen with FP-SAL
and a higher rate of pneumonia was observed. As one of the largest trials in COPD, and with a 3-year
follow-up, the TORCH trial3 was a landmark study and provided a validation point for our study.
We obtained individual patient data from the TORCH trial3 via www.clinicalstudydatarequest.com
(accessed 28 May 2021) for use in objective 1 (see Selection of participants).
Clinical Practice Research Datalink
The CPRD is a very large database of prospectively collected, anonymised UK population-based EHRs.
CPRD primary care records comprise ≈ 8–10% of the UK population and contain comprehensive
information on clinical diagnoses, prescribing, referrals, tests and demographic/lifestyle factors.9
To contribute to the database, general practices and other health centres must meet prespecified
standards for research-quality data (i.e. be ‘up to standard’). Data quality/validity are, therefore,
high and the data are nationally representative.9,10 A patient starts contributing follow-up time to
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the database at the date they join an ‘up-to-standard’ practice (or the date that their practice starts
contributing up-to-standard data) and stop contributing follow-up time on the date of their death,
their transfer out date (i.e. the date that they leave the database for reasons other than death) or
the last collection date for their practice. Linkage between the primary care records in CPRD and
HES is well established for > 60% of practices in the CPRD, providing a data set augmented with detailed
secondary care diagnostic and procedural records. Algorithms have been established to identify COPD,
COPD exacerbations, pneumonia (both hospital and primary care managed) and asthma in CPRD/HES-
linked data (including validated algorithms for COPD and exacerbations).11–13 A high-level overview of
these algorithms is provided in Table 1, and all diagnostic and therapeutic codelist files used to search the
CPRD and HES databases for exposure, outcome and covariate information described subsequently in
this report are available for download at https://datacompass.lshtm.ac.uk/1655/ (accessed 28 May 2021).
For body mass index (BMI) and smoking status, the algorithms we applied looked for the nearest status in
TABLE 1 Overview of algorithms used for detecting COPD, COPD exacerbations and pneumonia in CPRD and HES
Condition Study Algorithm descriptiona Validityb Other notes
COPD Quint et al.11 CPRD diagnostic (Read) code
for COPD
PPV: 87% (95% CI
78% to 92%)





l Eight algorithms presented




Rothnie et al.13 CPRD diagnostic (Read) code
for LRTI or AECOPD OR
A prescription of a COPD-
specific antibiotic combined
with OCS for 5–14 days OR
A record (Read code) of
two or more respiratory
symptoms of AECOPD with a
prescription of COPD-specific
antibiotics and/or OCS on the
same day
PPV: 86% (95% CI
83% to 88%)
Sensitivity: 63%
(95% CI 55% to
70%)






presented in total; PPVs
ranging from 61% to 100%
and sensitivities ranging
from 1.6% to 63%
Pneumonia Millet et al.12 CPRD diagnostic (Read) codes
and HES diagnostic (ICD-10)
codes for pneumonia
(identified as a subset of an
initial search for LRTI codes)
Records in both databases
within the 28 days considered
the same illness episode
No validation
performed
Asthma Nissen et al.14 CPRD diagnostic (Read) code
indicating asthma
PPV: 86% (95% CI
77% to 95%)
AECOPD, acute exacerbation of chronic obstructive pulmonary disease; CI, confidence interval; GP, general practitioner;
ICD-10, International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; LRTI, lower
respiratory tract infection; OCS, oral corticosteroid; PPV, positive predictive value.
a Main algorithm applied in this real-world effects study (details on other algorithms presented in paper provided in
the ‘other notes’ column where appropriate).
b Validity=measure of validity presented in article: result obtained (95% CI).
Reproduced with permission from Wing et al.1 This is an Open Access article distributed in accordance with the terms
of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build
upon this work, for commercial use, provided the original work is properly cited. See: https://creativecommons.org/
licenses/by/4.0/. The table includes minor additions and formatting changes to the original.
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the period – 1 year to + 1 month from the index date (preferred). If this was not available, then the nearest
in the period + 1 month to + 1 year after the index date was taken (second preferred). If this was not
available, then the nearest before – 1 year from the index date was taken (third preferred) and if this
not available, then we took the nearest after + 1 year from the index date (least preferred).
Selection of participants
Objective 1: validation of methods for measuring chronic obstructive pulmonary disease
medication effectiveness in electronic health record data by comparing with trial results
For objective 1, two analyses were performed: (1) FP-SAL compared with no FP-SAL (for comparing
with the TORCH trial3 FP-SAL vs. placebo analysis) and (2) FP-SAL compared with SAL only (for
comparing with the TORCH trial3 FP-SAL vs. SAL analysis). The selection procedures for each of these
analyses are detailed separately below.
FP-SAL exposed compared with unexposed analysis
Step 1: selection of all potentially eligible patients
An initial cohort was selected from all HES-linked patients actively registered in the CPRD between
1 January 2004 and 1 January 2017, who fulfilled the TORCH trial3 inclusion criteria (Box 1).3 The date
that an individual met all inclusion criteria with at least 12 months prior registration in the CPRD was
the ‘eligible for the TORCH trial’3 inclusion date.
Step 2: selection of pool of unexposed patients
Patients who had time periods in which they were unexposed to FP-SAL on or after the ‘eligible for the
TORCH trial’3 inclusion date and who did not meet any of the TORCH trial3 drug exposure exclusion
criteria (see Box 1) were selected (Figure 2).3 The start of follow-up date (i.e. the index date) for the
unexposed time period was selected as a random date between the start and end of the unexposed
period (see Figure 2). Individuals in CPRD were able to contribute more than one such unexposed time
period to the total pool of unexposed time periods (see Figure 2) to avoid placing a restriction on a
study entry that would not have existed if the potential participants were going to be recruited to a
trial (i.e. they could have been recruited to a trial during any one of the eligible periods and we did not
want to restrict to only one of these periods at this stage just because we were performing a study
using data that had already been collected). Unexposed time periods were then removed from the
cohort if the patient met any of the remaining TORCH trial3 exclusion criteria prior to the index date.3
Step 3: selection of unexposed-to-FP-SAL people by 1 : 1 matching FP-SAL time periods to
TORCH trial3 participants
Each individual participant from the TORCH trial3 [obtained via www.clinicalstudydatarequest.com
(accessed 28 May 2021), as described Setting/data sources] was matched 1 : 1 with the closest available
unexposed-to-FP-SAL time period on the following TORCH trial3 baseline characteristics: age, sex, BMI,
1-year history of exacerbations requiring hospitalisation, history of cardiovascular disease and lung
function [forced expiratory volume in 1 second (FEV1)]. An individual could contribute only one unexposed
period to the final TORCH trial-matched3 unexposed cohort (see Figure 2) and, therefore, the output of this
step was a cohort of unexposed-to-FP-SAL people. This trial-matching step was performed to obtain an
unexposed cohort that was as similar as possible to that in the TORCH trial.3
Step 4: selection of exposed-to-FP-SAL time periods and application of TORCH trial3
exclusion criteria
We identified all prescriptions for FP-SAL that started (1) on or after the initial ‘eligible for the TORCH
trial’3 inclusion date (specified in step 1) and (2) at least 4 weeks after the end of a prescription for any
of the TORCH trial3 drugs. FP-SAL-exposed time periods were created with the index date assigned as
the start of a FP-SAL prescription. The same exclusion criteria as applied to the unexposed FP-SAL
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time periods (step 3) were applied. If an individual contributed time periods to both the unexposed
(step 2) and exposed (step 4) cohorts, they were contributing different periods of their person-time to
each cohort (pre-FP-SAL treatment for step 2 vs. post-FP-SAL treatment for step 4) (see Figure 2).
Step 5: selection of comparable FP-SAL-exposed participants by matching FP-SAL-exposed
time periods to FP-SAL-unexposed people
Using the index date baseline characteristics, propensity scores for receiving FP-SAL were calculated
for the (TORCH trial-matched3) FP-SAL-unexposed people selected in step 3 and the FP-SAL-exposed
time periods selected in step 4. Each FP-SAL-unexposed (TORCH trial-matched3) person selected in step
3 was matched 1 : 1 with the FP-SAL-exposed time period from step 4 with the closest propensity score.
We applied a matching without replacement approach, which meant that an individual could appear only
BOX 1 The TORCH trial3 inclusion and exclusion criteria
TORCH3 inclusion criteria applied to cohort
l A diagnosis of COPD.
l Aged 40–80 years.
l Smoking status of ‘current’ or ‘ex’.
l Lung function criteria of FEV1 < 60% predicted and a FEV1/FVC ratio of < 70%.
TORCH3 exclusion criteria applied to cohort
Previous drug exposure criteria
l Any exposure to any of the TORCH trial3 drugs (FP-SAL, SAL or FP) within the previous 4 weeks.
l Current use of a long-acting bronchodilator.a
l Current use of OCS therapy.b
Remaining exclusion criteria (after applying drug exposure criteria): all at any time prior to the index date
unless specified
l A diagnosis of asthma (within the previous 5 years).c
l A diagnosis for any (non-COPD) respiratory disorder.
l A record of lung surgery.
l A diagnosis of alpha-1 antitrypsin deficiency.
l A record of having received long-term oxygen therapy.
l Diagnoses for conditions likely to interfere with the TORCH trial3 or to cause death within the 3 years
following the index date.
l Record of an exacerbation requiring OCS therapy or hospitalisation during the period equivalent to the
trial ‘run-in’ period (i.e. the 2-week period following the index date).
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; OCS, oral corticosteroid.
a Current use of a long-acting bronchodilator defined in the CPRD population as any prescription for a long-acting
bronchodilator occurring within the period that one of the study drugs was prescribed (or that ended within
7 days prior to the start of a prescription for one of the study drugs).
b Current use of OCS therapy in the TORCH trial3 was defined as continuous use for > 6 weeks, with courses of
OCSs separated by a period of < 7 days considered as continuous use. We applied the same approach to the
CPRD population to define exclusion due to exposure to OCS.
c Asthma diagnosis based on a previously validated method for detecting cases of asthma in CPRD.14
Reproduced with permission from Wing et al.1 This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt
and build upon this work, for commercial use, provided the original work is properly cited. See: https://creative
commons.org/licenses/by/4.0/. The box includes minor additions and formatting changes to the original.
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FIGURE 2 Management of FP-SAL-exposed and FP-SAL-unexposed time periods in selection of people from the CPRD. Step 1: selection of all potentially eligible patients. Six example
patients in CPRD. Green arrow= date at which individual met TORCH trial3 inclusion criteria, grey time periods = FP-SAL exposed, white time periods = FP-SAL unexposed. Step 2:
selection of pool of unexposed patients. Unexposed time periods selected and exclusion criteria relating to drug exposures applied. An unexposed record index date is then assigned
as a random date within each unexposed period (indicated by diamond symbols) and further TORCH trial3 exclusion criteria applied based on this date. In this example, one unexposed
record from each of persons 1, 4 and 6 were excluded prior to step 3. Step 3: selection of unexposed-to-FP-SAL time periods by 1 : 1 matching to TORCH trial3 participants. Dotted red
lines indicate matching. Matching characteristics assessed on index date of specific unexposed time period and only one time period per person could be matched to the TORCH trial.3
Step 4: selection of exposed-to-FP-SAL time periods and application of TORCH trial3 exclusion criteria. In this example, one exposed time period from persons 3 and 6 was excluded
based on TORCH trial3 exclusion criteria. Step 5: selection of comparable FP-SAL-exposed participants. Pre matching there was one record per person for the FP-SA-unexposed cohort
and one or more per person for the FP-SAL-exposed cohort. After matching there were an equal number of each. Exposed and unexposed records then followed up and analysed from
index date onwards following an ‘intention-to-treat’ approach. Reproduced with permission from Wing et al.15 This is an Open Access article distributed in accordance with the terms of
the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is



























































































































































































































































































once as an exposed participant in the final propensity score-matched cohort, meaning that this step
selected FP-SAL-exposed participants from the initial pool of FP-SAL-exposed time periods. It was possible
for the same person to be included in the FP-SAL-unexposed and FP-SAL-exposed cohorts, with different
start of follow-up dates in each cohort. The matching of the (trial-matched) FP-SAL-unexposed cohort to
the FP-SAL-exposed cohort was performed to obtain a FP-SAL-exposed cohort that was as comparable
as possible to the (trial-matched) FP-SAL-unexposed cohort. Importantly, we did not apply matching to
the TORCH trial3 to select our FP-SAL-exposed group because we wanted to develop propensity score
methodology for obtaining balanced groups that could then be applied to the study of groups of patients
who were not included in the trial (i.e. groups that we would never be able to find to match to in a trial
because they were excluded from the trial) (see Objective 2: measurement of chronic obstructive pulmonary
disease treatment effects in patients excluded from trials).
Selection of participants: FP-SAL-exposed participants compared with
salmeterol-exposed participants
The participant selection approach was analogous to the FP-SAL-exposed compared with the
FP-SAL-unexposed participant selection, except that the comparator group selected was those
exposed to SAL (rather than those unexposed to FP-SAL). The resulting differences in participant
selection were as follows. For step 1, the study period was from 1 January 2000 to 1 January 2017
(increased to ensure sufficient numbers of eligible SAL-exposed individuals). For step 2, instead of
selecting unexposed-to-FP-SAL time periods occurring on or after the ‘eligible for the TORCH trial’3
inclusion date, we selected periods of SAL exposure. Individuals in the CPRD who had more than
one SAL-exposed eligibility period within their record were able to contribute more than once to
the pool of SAL-exposed participants (with the covariates and person-time contributed unique to
the specific SAL-exposed eligibility period). The index date for each SAL-exposed record was the
first date of the eligible SAL exposure period (i.e. the first day of the SAL prescription). All other
aspects of step 2 and steps 3–6 were then as described for the FP-SAL-exposed compared with
FP-SAL-unexposed participant selection (with SAL-exposed records in place of FP-SAL-unexposed
records wherever mentioned).
Objective 2: measurement of chronic obstructive pulmonary disease treatment effects in
patients excluded from trials
We selected separate cohorts of patients with a valid COPD diagnosis in the CPRD who would not
have been eligible for inclusion in the TORCH trial3 (and, therefore, also not eligible for our objective 1)
because of the following characteristics:
l aged > 80 years
l history of lung surgery
l history of long-term oxygen therapy
l evidence of drug/alcohol abuse
l an asthma diagnosis within the 5 years prior to study entry
l substantial comorbidity.
Separate cohorts were created and analysed for each of the specific characteristics listed, but in all
other respects the people selected for each cohort met the TORCH trial3 criteria (see Box 1).
In relation to substantial comorbidity, the TORCH trial3 required people to be excluded from the trial if
they had a serious uncontrolled disease with a likelihood of causing death within 3 years, and application
of criteria based up TORCH trial3 criteria in objective 1 allowed us to select these people (although we
recognise this criterion is subjective). Participants for each of the objective 2 cohorts were selected in a
similar fashion to the objective 1 cohort, with the amended eligibility criteria specified above applied
(i.e. step 1 was modified for selection of each of the objective 2 cohorts).
METHODS
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As for objective 1, each participant was allowed to have multiple FP-SAL-exposed and FP-SAL-unexposed
eligibility periods in their record (as described in Figure 2). In contrast to objective 1, there was no matching
of unexposed patients to TORCH trial3 patients, as we did not require a TORCH trial-analogous3 cohort for
this analysis (i.e. no step 3). Instead, we were specifically putting together cohorts of people who were not
included in the TORCH trial3 (and, therefore, would not be available or matching). All other selection steps
were as applied for objective 1, including the use of propensity score matching to obtain comparable
unexposed and exposed groups for analysis. This meant that our overall approach for objective 2 (and
objective 3) was to apply the TORCH trial3 inclusion and exclusion criteria to both the unexposed and
exposed groups, but modify the criteria according to the specific trial exclusion criteria that we were
interested in including (e.g. for those aged > 80 years we would include only those aged > 80 years, but
would still apply the other criteria detailed in Box 1). We would then skip the TORCH trial-matching3 step
(as there were no people over the age of 80 years in the TORCH trial3), but would apply our propensity
score matching approach to obtain comparable exposed and unexposed groups.
Objective 3: determination of treatment effects in an understudied disease stage
We selected separate cohorts of patients who had a valid COPD diagnosis in the CPRD and who
would not have been eligible for inclusion in the TORCH trial3 (or our objective 1) because of having
milder COPD than those recruited, as determined by spirometry. This cohort, therefore, included
periods of time from people who had a COPD diagnosis and whose spirometry measurements were a
> 60% predicted FEV1 (vs. the TORCH trial3 requirement of a < 60% FEV1) and/or a FEV1/forced vital
capacity (FVC) ratio of > 70% (vs. the TORCH trial3 requirement of a FEV1/FVC ratio of < 70%). We
are aware that study protocols often require the presence of obstructive spirometry (i.e. a FEV1/FVC
ratio of < 0.7) for identification of patients with COPD; however, based on previous validation work11
in the CPRD of the diagnosis of COPD and National Institute for Health and Care Excellence (NICE)
guidance that recommends that clinicians should ‘think about a diagnosis of COPD in younger people
who have symptoms of COPD, even when their FEV1/FVC ratio is above 0.7’,5 (© NICE 2010 Chronic
obstructive pulmonary disease in over 16s: diagnosis and management. Available from www.nice.org.uk/
guidance/cg101. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the
National Health Service in England. All NICE guidance is subject to regular review and may be updated
or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.)
our criteria for mild COPD will allow individuals to be included who have a diagnostic code for COPD
in the CPRD and a FEV1/FVC ratio of > 0.7.5,11
Exposures, outcomes and covariates
Exposures
For all objectives, exposures were determined using CPRD prescribing records and codelists for COPD
treatments [codelists are available from https://datacompass.lshtm.ac.uk/1655/ (accessed 28 May 2021)].
For all objectives, being prescribed FP-SAL was the primary exposure of interest and the comparison
exposure groups were (1) people not being prescribed FP-SAL and (2) people being prescribed SAL
only. In addition to FP-SAL and SAL, periods of exposure to oral corticosteroids (OCSs), ICS, FP, any
LAMA or any LABA were identified to facilitate application of the inclusion and exclusion criteria
described in Selection of participants.
For all drug exposures, duration of an exposure period was derived by multiplying the CPRD quantity
variable by any relevant dose information stored in the packtype variable and then dividing by the
value in the numeric daily dose CPRD variable. For example, for a prescription record with quantity = 1,
packtype = ‘60 dose inhaler’ and numeric daily dose = 2, the duration of the exposure period was
(1 × 60)/2 = 30 days. For prescription records where it was not possible to calculate this exposure
period (e.g. because of a missing quantity variable), the median value for that specific drug substance
and packtype combination was imputed as the exposure duration. To attempt to account for any
uncertainty in the end date of an exposure period (e.g. because of people not taking the medicine as
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directed or relying on additional medication previously prescribed and kept at home), a grace period of
half the median duration for the specific drug substance/pack type combination was added to the
calculated exposure duration to estimate the end date of the exposure period.
Outcomes
Outcomes were COPD exacerbation, all-cause mortality, pneumonia and time to treatment
discontinuation, and these were defined as follows:
l COPD exacerbation – defined using a CPRD-HES algorithm that was developed previously by one
of the co-authors of this study.11
l All-cause mortality – recorded in Office for National Statistics mortality statistics (i.e. data that are
linked to CPRD data).
l Pneumonia – defined using a CPRD-HES algorithm that was published previously by authors of
this study.12
l Time to COPD treatment discontinuation – treatment discontinuation classified as a period of
≥ 90 days with no further prescription for the specific drug.
Covariates
Covariates available for inclusion in the propensity score models included lung function, age, sex,
alcohol consumption, vascular disease, prescriptions for aspirin or statins, prior treatment with
other COPD medication, type 2 diabetes, history of cancer, renal disease and health-care utilisation
(i.e. rate of consultations, hospitalisations, hospital procedures and drug prescriptions).
Handling missing data
Complete records analysis was applied, given the small numbers of missing data (only socioeconomic
status, alcohol consumption or BMI had any missing data, and all were < 5% missing).
Sample size considerations
Objective 1
Assuming a baseline conservative exacerbation rate of 0.5 per patient per year,11 we required a sample
of 408 patients per treatment group to detect a reduction in annual exacerbation rate of 0.4 per year,
with 80% power and 5% significance. Our estimated sample size based on feasibility work assessing
the number of people meeting TORCH trial3 inclusion criteria was ≈ 12,000, providing ample power for
the main outcomes of interest but also allowing stratification by patient characteristics to determine
stratified results. For example, to detect a reduction from 0.5 to 0.4 exacerbations per year with 80%
power and 1% significance we would have needed ≈ 600 people in each treatment group.
Objectives 2 and 3
We were also confident that we would have sufficient numbers to allow well-powered analyses for
objectives 2 and 3. For example, a feasibility count looking at the number of people aged > 80 years
eligible for inclusion in objective 2 estimated that there would be > 2000 people in each exposure group.
We were aware that further application of TORCH trial3 exclusion criteria would lessen sample sizes
further, but it was not possible to estimate the extent that this would happen from the data that were
available to us prior to undertaking the study.
Blinding
Ascertainment of all outcomes was performed using pre-existing automated algorithms for detecting
these outcomes in the CPRD (as detailed in Outcomes). Although the data management was performed
separately for each drug exposure and, therefore, the person performing the analysis knew which
exposure they were obtaining outcomes for at this stage, the code used was identical for each exposure
and no edits to the code were permitted based on knowledge of exposure status.
METHODS
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Statistical analysis
Propensity score for addressing confounding
The propensity score for objective 1 was constructed using the principle that predictors of the exposure
(i.e. FP-SAL) and outcome (i.e. exacerbations, mortality and pneumonia) or outcome only should be
included. We considered a wide range of variables as the pool of initial variables for inclusion (as listed
in Covariates) based on a priori knowledge of potential association with exposure or outcome, such as
age, sex, BMI, alcohol consumption and a wide range of comorbidities (e.g. type 2 diabetes, coronary
heart disease, cerebrovascular disease, peripheral vascular disease, heart failure, hypertension, renal
disease and cancer). We also considered adjusting for health-care utilisation intensity (e.g. number of
prior visits, hospitalisations, number of distinct medications used, number of procedures), as these are
generic correlates of disease state and the likelihood of recording completeness. Our group has
substantial prior experience of building propensity models.16–19
For us to then select variables for inclusion in the propensity score, we removed those variables
from the pool of initial variables not associated with outcome in crude analysis before applying
multivariable logistic regression (on drug exposure status) to generate propensity scores.1 Variables
were selected for inclusion in the final propensity score multivariable logistic regression model using
log-likelihood ratio tests (LRTs) for goodness of fit. Starting from an initial fully adjusted model that
included all initial variables found to be associated with outcome, goodness of fit was tested after
removing variables sequentially from the logistic regression model (starting with the variable most
weakly associated with exposure in the fully adjusted model). Variables with a LRT p-value > 0.1 were
removed from the model until all variables remaining in the model had a LRT p-value < 0.1. These
remaining variables were the final variables that we used to calculate the propensity score. Separate
propensity scores were developed in this way for each outcome. Standardised differences were used
to assess any residual imbalances after matching (with a standardised difference > 0.1 indicating
substantial/important imbalance).18
The variable list used for the propensity score model obtained in objective 1 was the basis for
propensity score modelling in objectives 2 and 3, but additional variables from the pool of initial
variables were also considered, given the different nature of the patient populations being studied
in these objectives. We also assessed the impact of adjusting for the propensity score (rather than
matching) for these analyses.
Methods of analysis
For all objectives, comparisons were made according to FP-SAL (or other drugs being analysed, as
specified in Exposures) status for rate of COPD exacerbation, pneumonia and mortality over 3 years. All
analyses were performed according to the ‘intention-to-treat’ principle (as was carried out in the TORCH
trial3), meaning that if a participant entered the study as either an exposed or an unexposed participant
then they would remain assigned to that exposure category for the entire duration of their follow-up
(irrespective as to whether or not their true exposure status changes). For exacerbations, a negative
binomial model was used, accounting for variability between patients in the number and frequency of
exacerbations, with the number of exacerbations as the outcome and the log of treated time as an offset
variable. Time to mortality and treatment change was analysed using Cox proportional hazards regression.
Risk of pneumonia was analysed using Poisson regression. This mirrors the TORCH trial3 end points of
major benefit and harm.We anticipated that the propensity matching process would allow us to assemble
treated and untreated groups that were very similar with respect to baseline characteristics, except FP-SAL
treatment status. However, this was tested by assessing standardised differences for each baseline variable.
If substantial differences were noted for important variables, we made further adjustments to the statistical
models. This could also include examining the effect of using a greedy matching approach (i.e. where
once a match is made it is fixed) compared with an optimal matching approach (i.e. where the algorithm
reconsiders all previously made matches before making a new match) to obtain the closest propensity
score match and/or matching at a ratio other than 1 : 1.19
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Validation of results against the TORCH trial3
Our findings were validated against the TORCH trial3 as part of objective 1 by determining whether or
not results of the CPRD FP-SAL compared with no FP-SAL treatment analysis were compatible with
the TORCH trial3 exacerbations rate ratio for FP-SAL compared with placebo [0.75, 95% confidence
interval (CI) 0.69 to 0.81]. This outcome was selected because it is an outcome of key significance for
people with COPD5 and the result in TORCH trial3 shows a clear benefit with 95% confidence limits
of < 1. We set two criteria that needed to be met for us to conclude that results were consistent.
First, the effect size needed to be clinically comparable with TORCH trial3 findings (i.e. the rate ratio
for exacerbations in the CPRD had to be between 0.65 and 0.9). This range was deliberately not
symmetrical around the TORCH trial3 estimate of 0.75, as we anticipated that the treatment effect in
routine clinical care would be weaker than that seen in the optimised setting of a randomised trial. We
recognised that this rule could be met with a poorly powered, inconclusive result, and so a second
criterion was that the 95% CI for the rate ratio had to exclude 1. For the FP-SAL with SAL alone
comparison (see Exposures), the 95% CI also needed to exclude 1 and the rate ratio had to be between
0.81 and 0.95 (compared with the TORCH trial3 FP-SAL vs. SAL result of 0.88, 95% CI 0.81 to 0.95).
Sensitivity analyses
Handling measurement of adherence to medication
We considered that adherence to issued prescribing in general practice is likely to vary according to
the treatment issued. For example, short-course antibiotic treatment is notoriously not well adhered
to, whereas long-term life-saving treatment, such as antiretroviral medication, is more likely to be
taken as prescribed. Although we were not aware of published figures for adherence for COPD
medication in UK general practice, we reviewed the records for a random sample of 30 people with
COPD starting treatment with FP-SAL to look at adherence patterns over the course of 1 year. Of
30 patients, 20 (67%) were still receiving seretide (FP-SAL) 1 year after starting treatment. Of the
20 patients who received seretide for a full year, 15 (75%) received sufficient prescriptions to suggest
at least 50% adherence over the year and eight (40%) had sufficient prescriptions to suggest ≥ 80%
adherence. As expected, we considered that this suggested that (1) adherence is likely to be poorer in
routine clinical care than in the trial population (in the TORCH trial3 80% of participants were estimated
to have adherence at ≥ 80%) and (2) there is a wide range of adherence in routine care. Although we
acknowledge that prescribing can be only a proxy for used medication, we believed that it was not an
unreasonable assumption that the amount of medication prescribed would be correlated with the
amount consumed. We aimed to assess adherence for the cohort that we select for objective 1 beyond
1 year and report the findings. In the event that our analyses in objective 1 detected a null or poorer
treatment effect than anticipated, we planned to conduct a sensitivity analysis restricted to people
estimated to be covered by FP-SAL treatment for 80% of their follow-up.
Misclassification of (1) drug exposure periods and (2) outcome status
We considered that it would be possible that an individual may still be exposed to FP-SAL for some
time after a prescription has finished (e.g. if they have medication at home that they have not used
from a previous prescription). This would mean that people may become eligible for inclusion in the
unexposed group while they are actually still exposed. We planned to conduct a sensitivity analysis if
our results from objective 1 differed from the TORCH trial3 results. In this analysis, we would include
an additional (grace) exposed period that was equivalent to the length of a single prescription at the
end of each actual exposed period and only classify individuals as eligible for inclusion as unexposed at
the end of this additional period.
Misclassification of outcome can also have an impact on our results, given the routine nature of
the data. Our initial approach for the detection of COPD exacerbations was to use a validated case
definition from previous work that maximises positive predictive value while maintaining a relatively
high sensitivity.13 We therefore planned to perform a sensitivity analysis in which we assessed the
impact of applying the alternative case definitions for COPD exacerbations from this publication if our
objective 1 results differed from the TORCH trial.3
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Safety reporting and disclosure
As this study was a non-interventional study that used stored electronic health data in the UK CPRD
(with no recruitment of patients or intervention), there was no requirement for safety reporting
or disclosure.
Deviations from original protocol
l In objective 3, when looking at people with milder COPD, as defined by spirometry, we originally
specified that we would also look at people with no exacerbations at all in the year post COPD
diagnosis. However, we decided not to analyse this outcome because we were already looking at a
milder group, as defined by spirometry, and had limited time, as we effectively had to perform the
main data management and analysis steps twice (i.e. once for the comparison of FP-SAL with no
FP-SAL and then once for the comparison of FP-SAL with SAL because the FP-SAL and no FP-SAL
comparison produced results that were different from the TORCH trial3).
l For objective 2, there were a number of subgroups we planned to analyse, but were unable to
because of small numbers in these groups. These subgroups were people with a history of lung
surgery, people with a history of long-term oxygen therapy, people with substantial comorbidity or
people with evidence of drug/alcohol abuse. See Chapter 3, Note on results presented in results and
discussion part 2 for an overview of the actual numbers available for analysis from these groups.
l For objectives 1–3, in the protocol there were secondary analyses specified where we would repeat
each analysis comparing COPD treatments other than FP-SAL with no treatment (e.g. no treatment
vs. LABA, LAMA, LABA + LAMA, LABA + ICS other than FP-SAL and LABA + LAMA + ICS). We did
not perform these secondary analyses comparing these exposures with no treatment because of the
amount of work we had to do in repeating our primary analyses (i.e. FP-SAL vs. no FP-SAL followed
by FP-SAL vs. SAL), but have specified comparing these treatments with SAL as future research (see
Chapter 4, Prioritised list of recommendations for future research). However, the specific comparisons
would need updated based on updated NICE guidance20 published since the start of the project.
Patient and public involvement
We invited four patient and public representatives to be involved and advise on the project [via Breath
Easy, www.blf.org.uk/support-for-you/breathe-easy (accessed 1 June 2021)], one of whom accepted our
invitation and attended each of the four Steering Group meetings that took place during the project.
During these meetings, the patient and public involvement representative provided feedback on whether
or not the results we were presenting were clear and understandable, provided feedback on our plans on
next steps based on results and provided insight on aspects of COPD treatment from a COPD patient’s
perspective (e.g. in relation to how a patient might adhere to/not adhere to COPD medication, and how
a patient might typically go about managing COPD medications, which had been prescribed in UK
primary care, at home).
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Chapter 3 Results and discussion
Organisation of results and discussion section
The results and discussion section is organised into two parts, as illustrated in Table 2. We have
organised the chapter in this way because the choice of analysis in the second part was determined by
content in both the results and the discussion of analysis in the first part. Therefore, the most logical
way to present the results and discussion was a single chapter that is split into two parts (see Table 2).
Results and discussion part 1: analysis of chronic obstructive pulmonary
disease treatment effects in a TORCH trial-analogous3 cohort (objective 1)
Results
Participants
FP-SAL exposed compared with FP-SAL unexposed
Between 1 January 2004 and 1 January 2017 there were 125,671 people in the CPRD with a
diagnosis of COPD, 73,889 (59%) of whom were from HES-linked CPRD practices (Figure 3).
Application of TORCH trial3 inclusion criteria reduced this to 18,715 people, contributing 35,746
unexposed-to-FP-SAL time periods and 26,390 exposed-to-FP-SAL time periods. After applying
TORCH trial3 exclusion criteria, dropping records with missing covariate data and matching the
unexposed patients to TORCH trial3 participants, there were 4196 unexposed patients available for
propensity score matching to 10,463 FP-SAL-exposed time periods. The final propensity score-matched
cohorts included 2652 patients in each exposure group for the exacerbations analysis, 2708 patients in
each exposure group for mortality and 2779 patients in each exposure group for pneumonia.
FP-SAL exposed compared with SAL exposed
For the FP-SAL compared with SAL analysis, there were 154,785 people with a diagnosis of COPD in
the CPRD between 1 January 2000 and 1 January 2017, 91,733 (59%) of whom were from HES-linked
CPRD practices (Figure 4). A total of 1146 SAL-exposed patients were available for propensity score
matching to 11,235 FP-SAL-exposed periods. The final propensity score-matched cohorts included
991 (exacerbations), 432 (mortality), 935 (pneumonia) and 996 (treatment discontinuation) patients
per exposure group.
TABLE 2 Organisation of results and discussion section
Results and
discussion




1 COPD treatment effects in
a TORCH trial-analogous3
cohort






2 COPD treatment effects in
(a) patients excluded from
trials and (b) patients with
milder COPD
FP-SAL vs. SAL Exacerbations, mortality,
pneumonia
2 and 3
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People in  the CPRD linked to HES with a f irst diagnosis of COPD recorded in  the CPRD between 1 January 2004 and 1 January 2017
(n = 73,889)
Did not meet TORCH trial3 inclusion criteria (n = 55,174) due to
• Age, n = 11,990
• Smoking status, n = 5646
• No lung function records, n = 19,198
• Lung function criteria, n = 18,340
People in the CPRD who meet TORCH trial3 inclusion criteria
(n = 18,715)
FP-SAL-unexposed time periods
n = 35,746 (from 18,242 people)
FP-SAL-exposed time periods
n = 26,390 (from 9513 people)
Excluded time periods because of
 TORCH trial3 exclusion criteria
(n = 18,477)
Detail
• Current/previous exposure to COPD drugs, n = 2931
• Asthma, n = 12,795
• Pre-existing lung conditions, n = 1149
• Substance abuse, n = 386
• Oxygen therapy, n = 107
• Likely death or study interference, n = 827
• Run-in exacerbation, n = 282
Excluded time periods because of
 TORCH trial3 exclusion criteria
(n = 15,336)
Detail
• Current/previous exposure to COPD drugs, n = 1945
• Asthma, n = 11,110
• Pre-existing lung conditions, n = 884
• Substance abuse, n = 300
• Oxygen therapy, n = 102
• Likely death or study interference, n = 578
• Run-in exacerbation, n = 417
Missing BMI
(n = 56)







Exposed time periods after applying TORCH trial3 exclusion
criteria n = 11,054 (from 4513 people)
Unexposed time periods after applying TORCH trial3 exclusion
criteria n = 17,269 (from 10,257 people)
Unexposed time periods ready for
matching to TORCH trial3
n = 17,176 (from 10,193 patients)
People not matched to TORCH trial3
(n = 5834)










Unexposed people ready for propensity score matching
(n = 4196)
Exposed time periods ready for propensity score matching
n = 10,463 (from 4259 people)
Propensity score
matched toUnmatched
• Exacerbations, n = 1607
• Mortality, n = 1551
• Pneumonia, n = 1480
Unmatched
• Exacerbations, n = 1544
• Mortality, n = 1488
• Pneumonia, n = 1417












FIGURE 3 Flow of number of individuals included in the exposed to FP-SAL vs. unexposed to FP-SAL cohort analysis.
Note that the current/previous use of COPD drugs relates to any of the drugs studied in the TORCH trial,3 long-acting
bronchodilators and OCSs (see Box 1). SES, socioeconomic status.
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People in the CPRD linked to HES with a f irst diagnosis of COPD recorded in the CPRD between 1 January 2000 and 1 January 2017
(n = 91,733)
Did not meet TORCH trial3 inclusion criteria (n = 69,267) due to
• Age, n = 14,683
• Smoking status, n = 10,333
• No lung function records, n = 23,783
• Lung function criteria, n = 20,468
People in the CPRD who meet TORCH trial3 inclusion criteria
(n = 22,466)
SAL-exposed time periods
n = 48,280 (from 3408 people)
FP-SAL-exposed time periods
n = 33,805 (from 11,879 people)
Excluded time periods due to
 TORCH trial3 exclusion criteria
(n = 42,584)
Detail
• Exposure to TORCH trial3 drugs or OCS, n = 33,748
• Exposure to long-acting bronchodilator, n = 1102
• Asthma, n = 6692
• Pre-existing lung conditions, n = 483
• Substance abuse, n = 89
• Oxygen therapy, n = 29
• Likely death or study interference, n = 308
• Run-in exacerbation, n = 133
Excluded time periods due to
TORCH trial3 exclusion criteria
(n = 21,918)
Detail
• Exposure to TORCH trial3 drugs or OCS, n = 5978
• Exposure to long-acting bronchodilator, n = 1289
• Asthma, n = 12,249
• Pre-existing lung conditions, n = 996
• Substance abuse, n = 289
• Oxygen therapy, n = 145
• Likely death or study interference, n = 577
• Run-in exacerbation, n = 395
Missing BMI
(n = 69)







FP-SAL-exposed time periods after applying TORCH trial3
exclusion criteria n = 11,887 (from 4798 people)
SAL-exposed time periods after applying TORCH trial3
exclusion criteria n = 5696 (from 1399 people)
SAL-exposed time periods ready for
matching to TORCH trial3
n = 5671 (from 1392 people)
People not matched to TORCH trial3
(n = 184)










SAL-exposed people ready for propensity score matching
(n = 1146)
FP-SAL-exposed time periods ready for propensity score
matching n = 11,235 (from 4523 people)
Propensity score
matched toUnmatched
• Exacerbations, n = 3580
• Mortality, n = 3445
• Pneumonia, n = 3588
• Treatment discontinued, n = 4176
Unmatched
• Exacerbations, n = 155
• Mortality, n = 714
• Pneumonia, n = 211
• Treatment discontinued, n = 150
















FIGURE 4 Flow of number of individuals included in the exposed to FP-SAL vs. exposed to SAL cohort analysis.
SES, socioeconomic status.
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Application of TORCH trial3 inclusion/exclusion criteria and matching to the
TORCH trial3
Applying the TORCH trial3 inclusion/exclusion criteria and matching to the TORCH trial3 resulted in
cohorts that were much more similar to those recruited to the TORCH trial3 (e.g. FEV1% of predicted
for the FP-SAL vs. unexposed to FP-SAL analysis was 66.3 in the CPRD before applying any criteria or
matching, compared to 47.2 after these steps, compared to a TORCH3 placebo group value of 44.2)
(see Table 3). The largest residual difference to the TORCH trial3 placebo group was for prior
cardiovascular disease for both comparisons (Tables 3 and 4).
Propensity score matching of Clinical Practice Research Datalink cohorts
Details of the variables included in the final propensity score models are provided in Table 5.
TABLE 3 Characteristics of the CPRD non-interventional COPD cohort for the FP-SAL vs. no FP-SAL comparison,
showing (1) the cohort of all HES-linked patients in the CPRD with a COPD diagnosis, (2) the cohort after applying
TORCH trial3 inclusion/exclusion criteria (unexposed to FP-SAL group only) and (3) the cohort after applying TORCH
trial3 inclusion/criteria and matching to TORCH trial3 participants (unexposed to FP-SAL group only), in comparison with


























65 (58–74) 68.0 (61.0–73.0) 67.0 (61.0–73.0) 65 (59–71)
Sex (male), n (%) 24,182 (53) 10,671 (62) 3307 (76) 1163 (76)
BMI (kg/m2), median
(IQR)




0.1 (0.9) 0.0 (0.3) 0.1 (0.3) 0.2 (0.7)
History of cardiovascular
disease
11,564 (25) 4888 (28) 1987 (46) 784 (51)
Lung function: FEV1 per
cent of predicted,
median (IQR)
66.3 (51.6–81.33) 51.7 (41.8–59.0) 47.2 (37.3–56.1) 44.2 (35.0–54.0)
IQR, interquartile range; SD, standard deviation.
a Includes all people in the CPRD with a diagnosis for COPD between 2004 and 2016 who have spirometry data
recorded. All variables in this column measured at the date of COPD diagnosis recorded in the CPRD.
b Inclusion criteria: diagnosis of COPD, aged 40–80 years, all current or ex-smokers, lung function of FEV1 < 60%
predicted and a FEV1/FVC ratio of < 70%. Exclusion criteria: diagnosis of asthma within the previous 5 years,
diagnosis for any non-COPD respiratory disorder, a record of lung surgery, a diagnosis of alpha-1 antitrypsin
deficiency, evidence of drug or alcohol abuse, a record of having received long-term oxygen therapy, diagnoses likely
to interfere with the TORCH trial3 or cause death within 3 years, current use of OCS therapy and any exposure
to FP-SAL within the previous 4 weeks. All variables in this column were measured at the earliest date that all
inclusion criteria were met and all exclusion criteria were not met.
c Matched on all variables in this table.
d Within prior year.
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TABLE 4 Characteristics of the CPRD non-interventional COPD cohort for the FP-SAL vs. SAL analysis showing (1) the
cohort of patients in the CPRD with a COPD diagnosis (2) the cohort after applying TORCH3 inclusion/exclusion criteria
(exposed to SAL group) and (3) the cohort after applying TORCH3 and inclusion/criteria and matching to TORCH3



























66.0 (58.0–74.0) 68.0 (63.0–74.0) 68.0 (62.0–73.0) 65.1 (60.0–71.0)
Sex (male), n (%) 35,045 (53) 3415 (60) 767 (63) 1160 (76)
BMI (kg/m2), median
(IQR)




0.0 (0.3) 0.0 (0.1) 0.0 (0.2) 0.2 (0.6)
History of cardiovascular
disease
13,274 (25) 1689 (30) 374 (31) 807 (53)
Lung function: FEV1 per
cent of predicted,
median (IQR)
63.2 (49.1–76.8) 52.6 (43.4–61.1) 49.4 (40.5–57.1) 43.4 (33.8–53.4)
IQR, interquartile range; SD, standard deviation.
a Includes all people in the CPRD with a diagnosis for COPD between 2004 and 2016 who have spirometry data
recorded. All variables in this column measured at the date of first SAL exposure.
b Inclusion criteria: diagnosis of COPD, aged 40–80 years, all current or ex-smokers, lung function of FEV1< 60%
predicted and a FEV1/FVC ratio of < 70%. Exclusion criteria: diagnosis of asthma within the previous 5 years,
diagnosis for any non-COPD respiratory disorder, a record of lung surgery, a diagnosis of alpha-1 antitrypsin
deficiency, evidence of drug or alcohol abuse, a record of having received long-term oxygen therapy, diagnoses likely
to interfere with the TORCH trial3 or cause death within 3 years, current use of OCS therapy and any exposure to
any of the study drugs within the previous 4 weeks. All variables in this column were measured at the earliest date
that all inclusion criteria were met and all exclusion criteria were not met.
c Matched on all variables in this table.
d Within prior year.
TABLE 5 Variables included in the final propensity score models
Analysis Variables included in propensity score model Matching
FP-SAL vs. unexposed to FP-SAL analysis
Exacerbations Sex, age, FEV1, FEV1/FVC, BMI, year of index date, previous diagnosis
of cerebrovascular disease; having at least one prescription of
(1) statin, (2) ICS, (3) LABA – ICS combination therapy or (4) LAMA
in the previous year; and the frequency of consultations, prescriptions,
hospitalisations, hospital procedures and exacerbations in the
previous year
1 : 1 nearest neighbour,
callipera of 0.03
Mortality Sex, age, FEV1, FEV1/FVC, BMI, SES, previous diagnosis of
(1) coronary heart disease, (2) peripheral vascular disease or
(3) cerebrovascular disease; having at least one prescription
of (1) LAMA or (2) LABA – ICS combination therapy in the
previous year; and the frequency of consultations, prescriptions,
hospitalisations and exacerbations in the previous year
1 : 1 nearest neighbour,
calliper of 0.03
continued
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TABLE 5 Variables included in the final propensity score models (continued )
Analysis Variables included in propensity score model Matching
Pneumonia Sex, age, FEV1, FEV1/FVC, BMI, alcohol consumption, previous
diagnosis of (1) coronary heart disease, (2) peripheral vascular disease
or (3) cerebrovascular disease; having at least one prescription of
(1) LAMA or (2) aspirin in the previous year, and the frequency of
prescriptions, hospitalisations and exacerbations in the previous year
1 : 1 nearest neighbour,
calliper of 0.03
FP-SAL vs. SAL analysis
Exacerbations Sex, FEV1, previous diagnoses for (1) type 2 diabetes or (2) chronic
kidney disease, year of index date, having at least one prescription
of an ICS in the previous year, and the frequency of consultations,
hospitalisations and hospital procedures in the previous year
1 : 1 nearest neighbour,
calliper of 0.03
Mortality Sex, age, year of index date, BMI, SES, FEV1, FEV1/FVC, diagnoses
for (1) peripheral vascular disease, (2) coronary heart disease,
(3) cerebrovascular disease, (4) Type 2 diabetes, (5) cancer or
(6) chronic kidney disease; having at least one prescription of
(1) statin, (2) aspirin, (3) LAMA, (4) LABA or (5) LABA – ICS
combination therapy in the previous year; and the frequency of
consultations, exacerbations, prescriptions, hospitalisations and
hospital procedures in the previous year
1 : 1 nearest neighbour,
calliper of 0.03
Pneumonia FEV1, year of index date, SES, diagnoses for chronic kidney disease,
and the frequency of consultations, prescriptions, hospitalisations
and hospital procedures in the previous year




FEV1, FEV1/FVC, alcohol intake, SES, year of index date, diagnoses
for (1) peripheral vascular disease, (2) coronary heart disease,
(3) cancer or (4) chronic kidney disease; having at least one
prescription of (1) statin, (2) aspirin, (3) ICS or (4) LABA – ICS
combination therapy in the previous year; and the frequency of
consultations, exacerbations, prescriptions, hospitalisations and
hospital procedures in the previous year
1 : 1 nearest neighbour,
calliper of 0.03
SES, socioeconomic status.
a Calliper =maximum permitted difference in propensity score between matched pairs.
FP-SAL exposed compared with FP-SAL unexposed
Prior to propensity score matching, for the exacerbations, analysis differences by exposure status were
noted for sex, FEV1, BMI, prior exacerbations, coronary heart disease, peripheral vascular disease,
cerebrovascular disease, prescriptions for aspirin, COPD medications, number of general practitioner
(GP) consultations and number of distinct medications (Table 6). After propensity score matching, only
the differences with respect to coronary heart disease, peripheral vascular disease and LABA persisted
(see Table 6). Plots of propensity score distributions indicated close propensity score matching for
exacerbations and all other outcomes under study (Figure 5).
FP-SAL exposed compared with salmeterol exposed
For the FP-SAL compared with SAL exacerbations analysis, after propensity score matching, there were
notable imbalances in prior prescriptions for a LABA or an ICS and frequency of consultations, with
smaller imbalances for lung function, BMI, coronary heart disease, statin prescription, aspirin prescription,
LAMA, ICS plus LABA and prior GP consultations (Table 7). Plots of propensity score distribution indicated
that, overall, groups were well matched on propensity score for each outcome (see Figure 5).
Main results
FP-SAL exposed compared with FP-SAL unexposed
For the exacerbations analysis, the rate ratio in the propensity score-matched groups was 1.30 (95% CI
1.19 to 1.42) (Table 8). According to our prespecified protocol, this (harmful) association was not considered
to be consistent with the (protective) TORCH trial3 placebo-controlled result for the same outcome
(0.75, 95% CI 0.69 to 0.81).1 Similarly, our result for the mortality outcome [hazard ratio (HR) 1.11,
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TABLE 6 Characteristics of the exposed to FP-SAL vs. unexposed to FP-SAL cohort before and after propensity score matching for the exacerbations analysis (CPRD non-interventional
population)
Variable




(N= 10,463 exposed time




(N = 2652 people)
Exposed to FP-SAL
(N = 2652 people)
Standardised
difference
Age (years), median (IQR) 67 (61–73) 68 (62–74) 0.103 68 (61–73) 68 (62–74) 0.083
Sex (male), n (%) 3175 (76) 6515 (62) 0.293 1868 (70) 1850 (70) 0.015
Lung functiond
FEV1 per cent of predicted,
median (IQR)
47 (38–56) 50 (40–60) 0.297 49 (39–57) 48 (38–56) 0.024
FEV1 : FVC per cent, median (IQR) 53 (44–61) 53 (44–63) 0.073 53 (44–62) 52 (43–61) 0.045
BMI (kg/m2),d median (IQR) 26 (22–29) 26 (23–31) 0.191 26 (23–30) 26 (22–30) 0.024
Prior exacerbations,e mean (SD) 0.51 (0.92) 0.66 (1.13) 0.148 0.56 (0.96) 0.62 (1.04) 0.060
Cardiovascular disease, n (%)f
Coronary heart disease 1114 (27) 1783 (17) 0.232 720 (27) 441 (17) 0.257
Peripheral vascular disease 390 (9) 648 (6) 0.116 253 (10) 166 (6) 0.122
Cerebrovascular disease 434 (10) 714 (7) 0.126 212 (8) 222 (8) 0.014
Other atherosclerosis 11 (0) 20 (0) 0.015 7 (0) 7 (0) 0.008
Statin prescription, n (%)g 2066 (49) 4614 (44) 0.103 1227 (46) 1238 (47) 0.008
Aspirin prescription, n (%)g 1563 (37) 3129 (30) 0.156 954 (36) 828 (31) 0.101
Other COPD medication prescriptions, n (%)g
LABAh 295 (7) 333 (3) 0.175 197 (7) 106 (4) 0.148
ICSh 530 (13) 842 (8) 0.151 280 (11) 333 (13) 0.063
LAMAh 1450 (35) 6284 (60) 0.528 1166 (44) 1177 (44) 0.008





























































































































































































































































































TABLE 6 Characteristics of the exposed to FP-SAL vs. unexposed to FP-SAL cohort before and after propensity score matching for the exacerbations analysis (CPRD non-interventional
population) (continued )
Variable




(N= 10,463 exposed time




(N = 2652 people)
Exposed to FP-SAL
(N = 2652 people)
Standardised
difference
Type 2 diabetes, n (%)f 543 (13) 1496 (14) 0.040 373 (14) 337 (13) 0.04
History of cancer, n (%)f 696 (17) 2105 (20) 0.091 486 (18) 451 (17) 0.035
Chronic kidney disease, n (%)f 540 (13) 1477 (14) 0.037 389 (15) 333 (13) 0.062
Health-care utilisation, median (IQR)e
Number of GP consultations 21 (15–29) 16 (10–26) 0.409 18 (14–29) 16 (10–26) 0.143
Number of distinct medications 4 (2–7) 5 (3–8) 0.180 4 (2–7) 5 (3–8) 0.073
Number of hospitalisations 0 (0–1) 0 (0–1) 0.008 0 (0–1) 0 (0–1) 0.007
Number of hospital procedures 0 (0–0) 0 (0–1) 0.022 0 (0–0) 0 (0–0) 0.011
IQR, interquartile range; SD, standard deviation.
a See Table 5 for list of variables included in final exacerbations propensity score model. Variables in this table that were included in the propensity score are in bold.
b TORCH trial3 inclusion/exclusion criteria applied and matched to TORCH trial3 individual patient data.
c TORCH trial3 inclusion/exclusion criteria applied.
d Closest record prior to the index date.
e All counted within the year prior to the index date, includes exacerbations recorded in primary or secondary care.
f Any diagnosis for condition prior to the index date.
g Number of people who had at least one prescription within the previous year.


























































Propensity score Propensity score
Propensity score
Propensity score
n = 2652 per matched group
Mortality
n = 2708 per matched group
Pneumonia
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FIGURE 5 Propensity score distributions before and after matching. (a) FP-SAL exposed (n = 10,926 before matching) vs.
FP-SAL unexposed (n= 4391 before matching); and (b) FP-SAL exposed (n= 11,235 before matching) vs. SAL exposed
(n= 1146 before matching). Treatment discontinuation not included for these analysis as only one of the exposure groups
was receiving treatment. (continued )
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Exacerbations


























Propensity score Propensity score
Propensity score Propensity score
Propensity score Propensity score
Propensity score
n = 991 per matched group
Mortality
n = 432 per matched group
Pneumonia
n = 935 per matched group
Time to treatment discontinuation 
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(b)
FIGURE 5 Propensity score distributions before and after matching. (a) FP-SAL exposed (n = 10,926 before matching) vs.
FP-SAL unexposed (n= 4391 before matching); and (b) FP-SAL exposed (n= 11,235 before matching) vs. SAL exposed
(n = 1146 before matching). Treatment discontinuation not included for these analysis as only one of the exposure groups
was receiving treatment.
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TABLE 7 Characteristics of the FP-SAL vs. SAL cohort before and after propensity score matching for the exacerbations analysis (CPRD non-interventional population)
Variable
Before propensity score matching After propensity scorea matching












Age (year), median (IQR) 68 (62–73) 68 (62–74) 0.051 68 (62–73) 67 (61–73) 0.038
Sex (male), n (%) 728 (64) 6960 (62) 0.033 628 (63) 637 (64) 0.019
Lung functiond
FEV1 per cent of predicted,
median (IQR)
49 (41–57) 50 (40–60) 0.272 50 (41–57) 49 (40–57) 0.107
FEV1 : FVC per cent, median (IQR) 53 (44–61) 53 (44–62) 0.022 53 (45–62) 51 (42–60) 0.122
BMI (kg/m2),d median (IQR) 26 (23–30) 26 (22–30) 0.057 26 (23–30) 26 (22–29) 0.123
Prior exacerbations,e mean (SD) 0.63 (1.02) 0.61 (1.07) 0.017 0.62 (1.01) 0.61 (1.03) 0.010
Cardiovascular disease, n (%)f
Coronary heart disease 207 (18) 1958 (17) 0.017 175 (18) 129 (13) 0.129
Peripheral vascular disease 71 (6) 749 (7) 0.019 62 (6) 62 (6) 0.000
Cerebrovascular disease 87 (8) 792 (7) 0.021 81 (8) 64 (6) 0.066
Other atherosclerosis 1 (0) 21 (0) 0.027 1 (0) 1 (0) 0.026
Statin prescription, n (%)g 462 (40) 4906 (44) 0.068 411 (41) 344 (35) 0.140
Aspirin prescription, n (%)g 333 (29) 3376 (30) 0.022 297 (30) 246 (25) 0.116
Other COPD medication prescriptions, n (%)g
LABAh 793 (69) 98 (1) 2.052 648 (65) 15 (2) 1.839
ICSh 419 (37) 862 (8) 0.742 275 (28) 387 (39) 0.241
LAMAh 477 (42) 6598 (59) 0.347 432 (44) 487 (49) 0.111





























































































































































































































































































TABLE 7 Characteristics of the FP-SAL vs. SAL cohort before and after propensity score matching for the exacerbations analysis (CPRD non-interventional population) (continued )
Variable
Before propensity score matching After propensity scorea matching












Type 2 diabetes, n (%)f 116 (10) 1549 (14) 0.113 101 (10) 100 (10) 0.003
History of cancer, n (%)f 200 (17) 2252 (20) 0.066 178 (18) 163 (16) 0.040
Chronic kidney disease, n (%)f 104 (9) 1535 (14) 0.145 89 (9) 85 (9) 0.014
Health-care utilisation, median (IQR)e
Number of GP consultations 15 (9–23) 16 (9–26) 0.765 15 (9–23) 15 (9 –25) 0.021
Number of distinct medications 5 (3–8) 5 (3–8) 0.039 5 (3–8) 5 (3–8) 0.019
Number of hospitalisations 0 (0–1) 0 (0–1) 0.063 0 (0–1) 0 (0–1) 0.005
Number of hospital procedures 0 (0–0) 0 (0–1) 0.065 0 (0–0) 0 (0–0) 0.035
IQR, interquartile range; SD, standard deviation.
a See Table 5 for list of variables included in final exacerbations propensity score model. Variables in this table that were included in the propensity score are in bold.
b TORCH trial3 inclusion/exclusion criteria applied and matched to individual TORCH trial3 patients.
c TORCH trial3 inclusion/exclusion criteria applied.
d Closest record prior to the index date.
e All counted within the year prior to the index date.
f Any diagnosis for condition prior to the index date.
g Number of people who had at least one prescription within the previous year.





































95% CI 0.95 to 1.26] was in the opposite direction to the TORCH trial3 placebo-controlled result
(HR 0.83, 95% CI 0.68 to 1.00). For the pneumonia analysis, we found weak evidence for a 14% increased
risk associated with FP-SAL [risk ratio (RR) 1.14, 95% CI 0.96 to 1.34], which was not consistent with
the stronger harmful association found by the TORCH trial3 placebo-controlled analysis (RR 1.59,
95% CI 1.35 to 1.88).
TABLE 8 Results for the analysis of exacerbations, mortality, pneumonia and time to treatment discontinuation for
FP-SAL vs. no FP-SAL (compared with TORCH trial3 results)
Analysis






(N= 1524) FP-SAL (N= 1533)
Exacerbations
Person-years at risk 9330 22,054
Events, n 4994 15,944
Rateb 0.53 0.72 1.13 0.85
Crude rate ratio (95% CI) 1 1.35 (1.28 to 1.43)
Propensity-matched rate
ratio (95% CI)
1 1.30 (1.19 to 1.42)c 1 0.75 (0.69 to 0.81)
Mortality
Person-years at risk 9330 22,054
Events, n 543 1245
Probabilityd at 3 years (%) 16.13 16.04 15.16 12.59
Crude HR (95% CI) 1 0.98 (0.88 to 1.08)
Propensity-matched HR
(95% CI)
1 1.11 (0.95 to 1.26)e 1 0.83 (0.68 to 1.00)
Pneumonia
Events, n 350 998
Per cent of total patients 8.34 9.54 12.31 19.60
Crude RR (95% CI) 1 1.14 (1.01 to 1.28)
Propensity-matched RR
(95% CI)
1 1.14 (0.96 to 1.34)f 1 1.59 (1.35 to 1.88)
Time to treatment discontinuationg
Person-years at risk 20,402
Events, n 2255




1 0.69 (0.62 to 0.78)
a Only results reported in the TORCH trial3 publication are shown.
b Per person per year.
c A total of 2652 people in each exposure group after propensity score matching. See Table 5 for list of variables
contributing to propensity score for exacerbations analysis.
d Probability of event at 3 years, calculated using a Cox proportional hazards model.
e A total of 2708 people in each exposure group after propensity score matching. See Table 5 for list of variables
contributing to propensity score for mortality analysis.
f A total of 2779 people in each exposure group after propensity score matching. See Table 5 for list of variables
contributing to propensity score for pneumonia analysis.
g Time to treatment discontinuation analysis not applicable to the unexposed to FP-SAL group.
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FP-SAL exposed compared with salmeterol exposed
For the exacerbations analysis, we obtained a propensity score-matched rate ratio of 0.85 (95% CI 0.74 to
0.97). According to our prespecified protocol, this (protective) effect was considered to be consistent with
the TORCH trial3 FP-SAL compared with SAL result for the same outcome (rate ratio 0.88, 95% CI 0.81
to 0.95) (Table 9).1 Similarly, our result for the mortality outcome (HR 0.93, 95% CI 0.65 to 1.32) was
consistent with the TORCH trial3 FP-SAL compared with SAL result (HR 0.93, 95% CI 0.77 to 1.13). For the
pneumonia analysis, we found evidence for a 39% increased risk associated with FP-SAL (RR 1.39, 95% CI
TABLE 9 Results for the analysis of exacerbations, mortality, pneumonia and time to treatment discontinuation for
FP-SAL vs. SAL (compared with TORCH trial3 results)
Analysis
CPRD non-interventional population TORCH trial3 populationa
SAL (N= 1146) FP-SAL (N= 11,235) SAL (N= 1521) FP-SAL (N= 1533)
Exacerbations
Person-years at risk 2566 24,062
Events, n 1515 14,034
Rateb 0.73 0.59 0.97 0.85
Crude rate ratio (95% CI) 1 0.80 (0.72 to 0.88)
Propensity-matched rate ratio
(95% CI)
1 0.85 (0.74 to 0.97)c 1 0.88 (0.81 to 0.95)
Mortality
Person-years at risk 2566 24,062
Events, n 138 1445
Probabilityd at 3 years (%) 15.09 16.84 13.48 12.59
Crude HR (95% CI) 1 1.12 (0.94 to 1.34)
Propensity-matched HR
(95% CI)
1 0.93 (0.65 to 1.32)e 1 0.93 (0.77 to 1.13)
Pneumonia
Events, n 86 1137
Per cent of total patients 7.50 10.12 13.29 19.60
Crude RR (95% CI) 1 1.35 (1.09 to 1.66)
Propensity-matched RR
(95% CI)
1 1.39 (1.04 to 1.87)f 1 1.47 (1.25 to 1.73)
Time to treatment discontinuation
Person-years at risk 1251 21,587
Events, n 740 2449
Probabilityd at 3 years (%) 77.02 28.04 36.40 33.70
Crude HR (95% CI) 1 0.22 (0.20 to 0.23)
Propensity-matched HR
(95% CI)
1 0.23 (0.20 to 0.27)g 1 0.89 (0.79 to 0.99)
a Only results reported in the TORCH trial3 publication are shown.
b Per person per year.
c A total of 991 people in each exposure group after propensity score matching. See Table 5 for list of variables
contributing to propensity score for exacerbations analysis.
d Probability of event at 3 years, calculated using a Cox proportional hazards model.
e A total of 443 people in each exposure group after propensity score matching. See Table 5 for list of variables
contributing to propensity score for mortality analysis.
f A total of 996 people in each exposure group after propensity score matching. See Table 5 for list of variables
contributing to propensity score for pneumonia analysis.
g A total of 935 people in each exposure group after propensity score matching. See Table 5 for list of variables
contributing to propensity score for time to treatment discontinuation analysis.
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1.04 to 1.87), which was also consistent with the harmful association found by the TORCH trial3 FP-SAL
compared with SAL analysis (RR 1.47, 95% CI 1.25 to 1.73). For the time to treatment discontinuation
analysis, the effect was apparently much stronger outside the trial setting (non-interventional HR 0.23,
95% CI 0.20 to 0.27 vs. TORCH trial3 non-interventional HR 0.89, 95% CI 0.79 to 0.99).
Analysis of impact of (1) TORCH trial3 matching and (2) TORCH trial3 criteria
(post hoc analysis)
Repeating the FP-SAL compared with SAL analysis and omitting the TORCH trial-matching3 step led to
an exacerbations rate ratio of 0.87 (95% CI 0.81 to 0.94) (Table 10), which is very similar to both the
main analysis and the TORCH trial3 result. By contrast, neither applying the TORCH trial3 criteria nor
matching led to a completely different effect estimate (rate ratio 1.64, 95% CI 1.52 to 1.77).
Discussion
We have demonstrated that methods applied to non-interventional data can generate results
comparable to active comparator trials for COPD treatment effects. By contrast, we found that the
same methods were unable to replicate placebo-controlled trial results.
Comparison with previous studies
Previous studies applying similar ‘trial-replication’ approaches
Although a number of papers have compared the designs of observational studies with RCTs21–26 and
some studies have generated results similar to an earlier or subsequent trial,27–29 to our knowledge
there are very few non-interventional studies that have set out to explicitly replicate a specific trial
cohort and its results.
Hernán et al.30 replicated the design and result of the Women’s Health Initiative31 randomised trial
on the effect of oestrogen/progestin therapy on coronary heart disease risk. Smeeth et al.32 analysed
the effect of statins on a range of health outcomes and replicated the Heart Protection Study33
randomised trial. Fralick et al.34 applied trial criteria and utilised propensity score matching to replicate
cardiovascular results from ONTARGET35 (ONgoing Telmisartan Alone and in combination with Ramipril
Global Endpoint Trial).
Previous studies of chronic obstructive pulmonary disease drug treatment effects
Results of five (LABA/ICS vs. LABA) interventional studies (including the TORCH trial3) were
summarised in a Cochrane review (rate ratio 0.76, 95% CI 0.68 to 0.84).36 Three out of these five studies
estimated effect sizes that were considerably greater than effect sizes reported in the TORCH trial.3
As this study mirrored the TORCH trial,3 our results aligned most closely to those of the TORCH trial.3
TABLE 10 Impact of choice of selection methods on ability to replicate trial results for the analysis of exacerbations in
people exposed to FP-SAL vs. people exposed to SAL
Rate ratio
n per exposure groupSAL FP-SAL (95% CI)
TORCH trial3 1 0.88 (0.81 to 0.95) 1524
CPRD non-interventional selection methoda
TORCH trial3 including/excluding criteria and
matched to bTORCH trial3
1 0.85 (0.74 to 0.97) 991
TORCH trial3 including/excluding criteria only 1 0.87 (0.81 to 0.94) 3225
No TORCH trial3 criteria or matching 1 1.64 (1.52 to 1.77) 5951
a SAL and FP-SAL groups propensity score matched for all selection methods.
b As per the main analysis and presented in Table 3.
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A number of studies have found strong survival benefits of ICS therapy after hospital discharge.36–38
After accounting for likely time-related biases that have an impact on these studies, a null effect was
obtained (rate ratio 0.94, 95% CI 0.81 to 1.09).39 The methodology we applied obtained a mortality
effect estimate comparable to the analysis designed to account for time-related biases (0.93, 95% CI
0.65 to 1.32).
In line with the TORCH trial,3 previous studies have found an increased risk of pneumonia associated
with ICS-containing treatments for COPD.36,40,41 Our result (RR 1.39, 95% CI 1.04 to 1.87) was
consistent with results of a meta-analysis of trials comparing LABA/ICS with LABA formulations
(OR 1.55, 95% CI 1.20 to 2.01)36 and very similar to a recent non-interventional study comparing
LABA/ICS with LAMA formulations (HR 1.37, 95% CI 1.17 to 1.60).42
Our 3-year probability of treatment discontinuation for FP-SAL (28%) is comparable to non-adherence
figures from previous non-interventional real-world data studies (49% and 43%).43,44 The probability of
discontinuation of SAL that we observed (77%) was higher than these two previous non-interventional
studies, leading to the discrepancy with the TORCH trial.3 We hypothesised that during our study
period a large proportion of the patients who would have been initially prescribed SAL would have
been likely to switch to FP-SAL because of prescribing decisions in primary care. A post hoc analysis
found that 43% of people prescribed SAL switched to FP-SAL during follow-up (vs. only 2% switching
from FP-SAL to SAL).
Implications and further work
When studying COPD treatment effects, if (1) the analysis is of active comparators, (2) trial exclusion
and inclusion criteria are applied and (3) the propensity score models that we developed for each
outcome are applied to balance exposure groups, then the results of studies carried out in routinely
collected non-interventional data can be considered robust in the sense that they will be highly
comparable to trial results. This now provides a methodological framework for being able to analyse
COPD drug treatment effects in real-world data, focusing on groups that were either not included or
under-represented in trials.1
Our inability to replicate placebo-controlled analyses suggests uncontrolled confounding by indication,
a well-known bias in pharmacoepidemiology that is highly likely to be present when performing a
comparison between people prescribed a drug and people not prescribed a drug.45–48 An established
design approach for addressing this bias is to perform an active comparator analysis (i.e. comparing
the effects of one medicine with another, rather than one medicine with no treatment).45–48 Based on
the likelihood of confounding by indication having an impact on our results compared with the results
of no treatment, we proceeded to perform the active comparator analysis and obtained results very
similar to the trial, which indicates that confounding by indication is highly likely to be the reason for
being unable to replicate placebo-controlled analyses in this setting.
One possibility for how this confounding by indication may be manifesting relates to an aspect of our
study design that allowed people to be included in both the exposed and unexposed cohorts (i.e. the
result we obtained could be strongly influenced by people initially in the unexposed group who are
relatively healthy but then get more sick over time and require FP-SAL treatment and end up in the
exposed group). However, in a post hoc analysis in which we dropped the 730 people (out of a total
of 2652 per group) who appeared in both cohorts, our effect estimate was nearly identical (RR 1.33,
95% CI 1.20 to 1.47). We do consider, however, that because COPD treatment is based on a step-up
approach, it is highly likely that patients not exposed to FP-SAL in routine primary care are generally
likely to be those with milder COPD.
An additional point that further explains our inability to replicate the placebo-controlled analysis relates
to the large difference in incidence rate between the TORCH trial3 placebo group (1.13 exacerbations/
person/year) and our FP-SAL-unexposed group (0.53 exacerbations/person/year). To investigate
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underlying reasons for this discrepancy, we performed a post hoc analysis in which we compared the
characteristics of the 1753 people from TORCH trial3 who were not able to be matched to our unexposed-
to-FP-SAL population in step 3 with those who were successfully matched.We found that those not
matched were younger (mean age 60.7 vs. 65.8 years), more sick (history of cardiovascular disease:
93% vs. 46%), had worse lung function (FEV1 34.9 vs. 45.9) and included a higher proportion of people
recruited from Eastern European trial sites (27% vs. 17%). People with these characteristics may have
been highly suitable for recruitment to the TORCH clinical trial,3 but are very difficult to find in UK
primary care, providing another reason why we were not able to replicate placebo-controlled analyses.
Furthermore, both TORCH trial3 placebo-assigned patients and patients in our own cohort were permitted
to use other COPD treatments during follow-up, but given the time and setting differences between our
FP-SAL-untreated group and the TORCH trial3 placebo group, people in our placebo group are much more
likely to have been prescribed, for example, an ICS during follow-up. More generally, it is also likely to be
challenging to obtain comparable absolute rates in emulated cohorts within a single country based on
historical international trials for reasons such as this.
Previous authors have gone as far to specifically recommend that when trying to emulate trial results
it is important to choose an active comparator trial.34 There are, however, examples in which placebo-
controlled analyses have been successfully replicated.30,32 One possibility is that replication of placebo-
controlled results works better when the drug studied is (1) preventative and (2) used in a generally
healthy cohort (e.g. the cited studies were of statins and of postmenopausal hormone therapy both
prescribed, in some instances, to people without a specific underlying chronic disease, in contrast to
the patients with COPD who received therapy in our study).We consider that further avenues of
research could be followed to understand if there remains a possibility of replicating placebo-controlled
studies within a non-interventional setting for COPD therapies. These could include the application of
high-dimensional propensity scores or the use of instrumental variables. Our work also suggests that
treatment discontinuation in the setting of non-interventional data may be driven by very different
factors to those seen in trials and, at least in the setting of COPD, may not be a useful outcome to study.
Interpretation of treatment discontinuation in routine data is challenging. For example, it is difficult to
establish from routinely collected data whether a patient has truly stopped taking their medicine or is
just taking the medicine differently than prescribed (e.g. is taking less than has been prescribed over a
longer period), a point that was emphasised by our patient and public involvement representative.
Finally, in our post hoc analysis, we found that the application of the trial-matching step did not confer
any advantage over the application of trial criteria alone in this setting. This suggests that treatment–
covariate interactions are not as critical as we initially thought in this therapeutic area.
Limitations
Some of the TORCH trial3 inclusion criteria were not fully assessable using CPRD data, meaning that
the inclusion/exclusion criteria are analogous with TORCH trial3 criteria, but we acknowledge that they
are not identical. For example, TORCH trial3 inclusion criteria included negative reversibility spirometry
criteria, but it was not possible to replicate this in the CPRD data. In addition, at entry to the TORCH
trial3 2-week run-in period all ICSs and inhaled long-acting bronchodilators were discontinued, but it
was not possible to ensure that all patients selected from the CPRD had discontinued these at the
start of the run-in period that we applied.
We originally planned to apply frequency of COPD therapy prescriptions in the previous year as a matching
character/criterion. In practice, this was not feasible. However, it appears that matching at this level of detail
was not required to be able to replicate trial results for active comparator analysis. Furthermore, it is clear
from Figures 3 and 4 that we had to drop around one-fifth of patients as they did not have spirometry
measurements recorded in the CPRD.This does mean that our initial study population may be missing key
groups of people who tend not to have their spirometry measured (e.g. people with COPDwho have the
least contact with the health services). This is a problem for any COPD research performed using routinely
collected primary care data, and although we acknowledge the issue we think that in this work it is likely to
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have minimal impact, as our aim was to create trial-analogous exposure groups that were highly comparable
to each other, not to select a highly generalisable sample.
Finally, within the TORCH trial,3 the dose of the fixed combination product FP-SAL was specified as
500 µg of FP and 50 µg of SAL (500/50) and the dose of SAL alone as 50 µg, whereas in our study we
did not limit to a specific dose. The reason for this is that dosage information is incompletely captured
in the CPRD. These are the only approved doses of FP-SAL and of SAL for COPD in the UK and so
we consider the doses that people were prescribed in our study would have been generally similar to
that administered in the TORCH trial,3 although we do acknowledge that there are likely to be some
differences in dosing between the TORCH trial3 and our cohort because of the long-term management
of patients with varying disease severity and varying concomitant conditions.
Conclusions
By replicating the COPD TORCH trial3 selection procedures and inclusion/exclusion criteria in real-
world data and developing propensity score models to account for any remaining differences between
groups, we were able to obtain highly comparable relative effect estimates to the TORCH trial3 active
comparator analysis for exacerbations, mortality and pneumonia.
Replication of placebo-controlled analyses was not possible. This is a not entirely unexpected result
because of the well-established fact that when comparing outcomes in people on treatment with
people not on treatment using non-interventional data, confounding relating to the difference in the
underlying health status of the two groups is usually too severe to address. We also found that trial
placebo groups in this therapeutic area may be much less healthy than people attending UK primary
care, having a further impact on the ability to replicate no-treatment comparisons. Further work to
investigate whether or not confounding by indication for no treatment comparisons can ever be
accounted for in this therapeutic area is warranted.
Performing active comparator analyses is a well-established design approach for minimising
confounding by indication. In addition, obtaining such similar results to the TORCH trial3 when
comparing active comparator results provides confidence that our methods will provide valid results
when used in other active comparator analyses within this therapeutic area. Application of the same
selection procedures and propensity score models developed here to active comparator analyses of
COPD drug treatment effects in groups under-represented or excluded from trials provides a practical
way for key evidence gaps to be filled in relation to whether or not one treatment is more effective
than another.
Results and discussion part 2: analysis of chronic obstructive pulmonary disease
treatment effects in (1) patients excluded from trials and (2) patients with milder
chronic obstructive pulmonary disease (objectives 2 and 3)
Note on results presented in results and discussion part 2
As presented and discussed in part 1 of this chapter (covering the primary analysis of objective 1), only
active comparator analyses (FP-SAL vs. SAL) obtained valid results for the analysis of treatment effects
(i.e. comparable to the TORCH trial3) using our methods. All of the primary analyses for objectives 2 and
3 (which are presented and discussed in this part of the results and discussion chapter) were, therefore,
also performed using the FP-SAL compared with SAL comparison. Of the original analyses planned in the
Chapter 2, Objective 1: validation of methods for measuring chronic obstructive pulmonary disease medication
effectiveness in electronic health record data by comparing with trial results and Objective 2: measurement
of chronic obstructive pulmonary disease treatment effects in patients excluded from trials, there were
insufficient numbers of people exposed to SAL for performing analyses of cohorts that were excluded
from the TORCH trial3 because of a history of lung surgery (n < 60 prior to propensity score matching),
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history of long-term oxygen therapy (n < 29), substantial comorbidity (i.e. a serious uncontrolled disease
with high likelihood of causing death within 3 years) (n < 60) or evidence of drug/alcohol abuse (n < 30).
Results are, therefore, presented for the analysis of the effect of FP-SAL compared with SAL on
exacerbations, mortality and pneumonia for the following groups that would have been excluded from
the TORCH trial:3
l people aged > 80 years
l people with an asthma diagnosis within the 5 years prior to inclusion
l people with milder COPD based on spirometry measurements (i.e. those who did not meet either or
both of the TORCH3 requirements of a FEV1 of < 60% predicted or a FEV1/FVC ratio of < 70%).
Results
Participants
After applying the TORCH trial3 exclusion criteria, as outlined in part 1, to the 91,733 people from
HES-linked CPRD practices with a diagnosis for COPD between 1 January 2000 and 1 January 2017
but with exclusion criteria altered relating to (1) aged > 80 years, (2) presence of asthma or (3) selection
of people with milder COPD based on spirometry, the final cohort sizes before and after propensity
score matching were as shown in Table 11.
TABLE 11 Number of people included in the analysis of CPRD COPD populations who would not have been eligible for
the TORCH trial3
Population for analysis SAL FP-SAL
People aged > 80 years
n per group before propensity score matching (n eligible time periods)a 194 (763) 670 (1645)




People with an asthma diagnosis within 5 years prior to inclusion
n per group before propensity score matching (n eligible time periods)a 1175 (5585) 3577 (9719)




People with milder COPD
n per group before propensity score matching (n eligible time periods)a 877 (3876) 2013 (4783)




a TORCH trial3 exclusions applied as detailed in Figure 4 (with the exception of the population characteristic under
study in the cohort, i.e. aged > 80, previous asthma or milder COPD).
b Details of the variables included in the final propensity score models for each outcome in each cohort are provided
in Table 12.
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Propensity score matching of cohorts of people who would have been excluded
from the TORCH trial3
Details of the variables included in the final propensity score models are provided in Table 12. As
described in Chapter 2, Propensity score for addressing confounding, variables from the pool of initial
variables that were not associated with the specific outcome under study were not included in the
multivariable logistic regression model used to generate the propensity score. This, therefore, meant
that the final propensity score models for each of the outcomes under study could contain a different
set of variables, depending on the outcome being studied. For example, for people with milder COPD,
TABLE 12 Variables included in the final propensity score models for the cohorts of people who would have been
excluded from the TORCH trial3
Outcome
being analysed Variables included in propensity score model Matching
Aged > 80 years
Exacerbations Alcohol intake, year of index date, previous diagnosis of chronic kidney
disease and having at least one prescription for (1) LABA or (2) ICS
1 : 1 nearest neighbour,
calliper of 0.03
Mortality Age, previous diagnosis of (1) chronic kidney disease or (2) cancer, year
of index date, having at least one prescription for a LABA, and frequency
of consultations and hospitalisations in the previous year
1 : 1 nearest neighbour,
calliper of 0.03
Pneumonia Age; FEV1/FVC; year of index date; previous diagnosis of chronic kidney
disease; having at least one prescription of a LABA; and frequency of
prescriptions, consultations and hospitalisations in the previous year
1 : 1 nearest neighbour,
calliper of 0.03
People with a prior asthma diagnosis
Exacerbations Sex; age; year of index date; FEV1; FEV1/FVC; BMI; previous diagnosis
for coronary heart disease; having at least one prescription for (1) LABA,
(2) ICS, (3) LAMA or (4) LABA – ICS combination therapy in the previous
year; and frequency of consultations, prescriptions, hospitalisations and
exacerbations in the previous year
1 : 1 nearest neighbour,
calliper of 0.03
Mortality Sex; age; index year; FEV1/FVC; BMI; alcohol intake; previous diagnosis
for (1) coronary heart disease, (2) peripheral vascular disease, (3) cancer
or (4) chronic kidney disease; having at least one prescription for
(1) statin, (2) aspirin, (3) ICS or (4) LAMA in the previous year; and
frequency of consultations, hospitalisations, procedures, exacerbations
in the previous year
1 : 1 nearest neighbour,
calliper of 0.03
Pneumonia Age; FEV1; index year; previous diagnosis for (1) coronary heart disease
or (2) peripheral vascular disease; having at least one prescription for
(1) LABA, (2) LAMA or (3) aspirin; and frequency of consultations,
hospitalisations and exacerbations in the previous year
1 : 1 nearest neighbour,
calliper of 0.03
People with mild COPD based on lung function
Exacerbations Previous diagnosis for (1) coronary heart disease, (2) peripheral vascular
disease or (3) cerebrovascular disease; having at least one prescription
for (1) aspirin, (2) LABA or (3) ICS; and frequency of consultations and
exacerbations in the previous year
1 : 1 nearest neighbour,
calliper of 0.03
Mortality Sex; age; BMI; previous diagnosis for (1) coronary heart disease,
(2) peripheral vascular disease, (3) cerebrovascular disease or (4) cancer;
having at least one prescription for (1) statin, (2) aspirin or (3) ICS; and
the frequency of prescriptions, hospitalisations, procedures and
exacerbations in the previous year
1 : 1 nearest neighbour,
calliper of 0.03
Pneumonia Index year; previous diagnosis for (1) coronary heart disease, (2) peripheral
vascular disease or (3) cardiovascular disease; having at least one
prescription for (1) aspirin or (2) LABA in the previous year; and the
frequency of consultations, hospitalisations, procedures and exacerbations
in the previous year
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the mortality propensity score included sex and age, but these variables did not end up in the final
propensity score for exacerbations or pneumonia. Although sex and age were associated with each
of these outcomes in crude analysis, exacerbations and pneumonia were dropped from the subsequent
multivariable logistic regression models that had drug exposure as an outcome (specified in Chapter 2,
Propensity score for addressing confounding) because of the lack of association with exposure after
multivariable adjustments.
People aged over 80 years
For the analysis of COPD exacerbations, prior to propensity score matching, differences by exposure
status were noted for sex, prior exacerbations, coronary heart disease, peripheral vascular disease,
cerebrovascular disease, prescriptions for COPD medications, chronic kidney disease and all measures
of health-care utilisation (Table 13). After propensity score matching, many differences persisted or
became apparent. Variables with substantial imbalance were age, sex, BMI, lung function, coronary
heart disease, peripheral vascular disease, statin use, prior LABA or LAMA use, type 2 diabetes, chronic
kidney disease and most measures of health-care utilisation.
Tables 17 and 18 in Appendix 1 show the balance of baseline variables for the analyses of mortality and
pneumonia outcomes, respectively. For both outcomes, the pattern of imbalances before and after
propensity score matching was very similar to that seen for COPD exacerbations.
People with an asthma diagnosis within 5 years prior to study entry
For the analysis of COPD exacerbations, prior to propensity score matching, differences by exposure
status were noted for age, BMI, prescriptions for COPD medications, number of GP consultations and
number of distinct medications prescribed (Table 14). After propensity score matching, many differences
were minimised, although imbalances are notable for peripheral vascular disease, cerebrovascular
disease, prior use of ICS and type 2 diabetes.
Tables 19 and 20 in Appendix 1 show the balance of baseline variables for the analyses of mortality and
pneumonia outcomes, respectively. After propensity score matching, imbalances were similarly reduced
for both outcomes. Minor differences from the exacerbations analysis were noted. For the mortality
analysis, post-matching imbalances were noted for FEV1 and prior use of LABA or ICS plus LABA
(see Appendix 1, Table 19). For pneumonia, post-matching imbalances were seen for LABA rather than
ICS use, BMI, ICS plus LABA and number of hospital procedures (see Appendix 1, Table 20).
People with mild chronic obstructive pulmonary disease (based on spirometry)
For the analysis of COPD exacerbations, prior to propensity score matching, differences by exposure
status were noted for FEV1 : FVC, prior exacerbations, coronary heart disease, peripheral vascular
disease, cerebrovascular disease, statin use, use of other COPD medications and most measures of
health-care utilisation (Table 15). After propensity score matching, most differences were minimised,
although small differences can be seen for number of distinct medications and number of hospitalisations.
Tables 21 and 22 in Appendix 1 show the balance of baseline variables for the analyses of mortality and
pneumonia outcomes, respectively. Similar imbalances to those seen for COPD exacerbations were seen
before propensity score matching. After propensity score matching, for the mortality outcome, imbalances
remained for FEV1 : FVC, prior use of LABA or ICS, history of cancer, number of GP consultations and
number of distinct medications (see Appendix 1, Table 21). For the pneumonia outcome, post-matching
imbalances can be seen for FEV1 : FVC, coronary heart disease and prior use of ICS (see Appendix 1, Table 22).
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TABLE 13 Characteristics of the aged > 80 years cohort before and after propensity score matching for the exacerbations analysis (FP-SAL vs. SAL) (CPRD non-interventional population)
Variable
Before propensity score matching After propensity score matching
Exposed to SAL














Age (years), median (IQR) 85 (83–88) 85 (83–88) 0.038 85 (82–87) 83 (82–85) 0.365
Sex (male), n (%) 517 (68) 976 (59) 0.176 57 (68) 50 (60) 0.174
Lung function, median (IQR)
FEV1 per cent of predicted 52 (46–59) 52 (41–59) 0.085 53 (43–59) 46 (37–56) 0.185
FEV1 : FVC per cent 55 (47–63) 55 (45–64) 0.092 52 (47–61) 49 (41–59) 0.326
BMI (kg/m2), median (IQR) 25 (22–28) 25 (22–28) 0.016 26 (22–29) 25 (21–28) 0.136
Prior exacerbations, mean (SD) 0.60 (0.97) 0.73 (1.16) 0.124 0.77 (1.17) 0.61 (0.84) 0.164
Cardiovascular disease, n (%)
Coronary heart disease 55 (7) 391 (24) 0.47 12 (14) 20 (24) 0.244
Peripheral vascular disease 21 (3) 158 (10) 0.288 3 (4) 9 (11) 0.28
Cerebrovascular disease 18 (2) 184 (11) 0.357 5 (6) 4 (5) 0.053
Other atherosclerosis 0 (0) 3 (0) 0.06 0 (0) 0 (0) 0 (0)
Statin prescription, n (%) 328 (43) 694 (42) 0.016 33 (39) 39 (46) 0.145
Aspirin prescription, n (%) 308 (40) 700 (43) 0.044 36 (43) 33 (39) 0.073
Other COPD medication prescriptions, n (%)
LABA 675 (88) 14 (1) 3.728 8 (10) 11 (13) 0.113
ICS 297 (39) 108 (7) 0.837 34 (40) 36 (43) 0.048
LAMA 244 (32) 901 (55) 0.473 35 (42) 44 (52) 0.216





































Before propensity score matching After propensity score matching
Exposed to SAL














Type 2 diabetes, n (%) 103 (13) 195 (12) 0.049 10 (12) 16 (19) 0.198
History of cancer, n (%) 282 (37) 545 (33) 0.08 28 (33) 26 (31) 0.051
Chronic kidney disease, n (%) 223 (29) 675 (41) 0.249 24 (29) 16 (19) 0.225
Health-care utilisation, median (IQR)
Number of GP consultations 49 (35–72) 19 (12–31) 1.161 52 (38–86) 19 (13–30) 1.453
Number of distinct medications 6 (3–9) 6 (3–10) 0.108 7 (4–9) 7 (5–10) 0.158
Number of hospitalisations 0 (0–1) 0 (0–1) 0.106 0 (0–1) 0 (0–1) 0.021
Number of hospital procedures 0 (0–1) 0 (0–2) 0.143 0 (0–1) 0 (0–2) 0.132




























































































































































































































































































TABLE 14 Characteristics of the cohort with an asthma diagnosis (during the previous 5 years) before and after propensity score matching for the exacerbations analysis (FP-SAL vs. SAL)
(CPRD non-interventional population)
Variable

















Age (years), median (IQR) 68 (61–73) 66 (59–72) 0.192 68 (62–73) 68 (61–74) 0.011
Sex (male), n (%) 2923 (52) 5409 (56) 0.067 276 (50) 282 (51) 0.022
Lung function, median (IQR)
FEV1 per cent of predicted 53 (42–62) 52 (41–61) 0.031 51 (42–60) 51 (41–60) 0.026
FEV1 : FVC per cent 55 (45–63) 55 (46–63) 0.022 53 (44–62) 53 (44–63) 0.029
BMI (kg/m2), median (IQR) 27 (24–31) 27 (24–32) 0.106 27 (23–31) 26 (23–30) 0.067
Prior exacerbations, mean (SD) 0.62 (1.02) 0.48 (1.01) 0.14 0.65 (1.02) 0.75 (1.19) 0.083
Cardiovascular disease, n (%)
Coronary heart disease 190 (3) 268 (3) 0.037 22 (4) 20 (4) 0.019
Peripheral vascular disease 60 (1) 60 (1) 0.05 16 (3) 5 (1) 0.146
Cerebrovascular disease 73 (1) 163 (2) 0.031 13 (2) 4 (1) 0.132
Other atherosclerosis 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Statin prescription, n (%) 2141 (38) 3742 (39) 0.003 189 (34) 186 (34) 0.011
Aspirin prescription, n (%) 1281 (23) 2401 (25) 0.042 134 (24) 131 (24) 0.013
Other COPD medication prescriptions, n (%)
LABA 5123 (92) 172 (2) 4.166 131 (24) 133 (24) 0.008
ICS 4177 (75) 1071 (11) 1.685 287 (52) 357 (64) 0.258
LAMA 1630 (29) 5193 (53) 0.508 173 (31) 188 (34) 0.058






















































Type 2 diabetes, n (%) 718 (13) 1429 (15) 0.054 70 (13) 51 (9) 0.110
History of cancer, n (%) 980 (18) 1629 (17) 0.021 98 (18) 88 (16) 0.048
Chronic kidney disease, n (%) 579 (10) 1142 (12) 0.044 49 (9) 56 (10) 0.043
Health-care utilisation, median (IQR)
Number of GP consultations 13 (8–21) 16 (9–26) 0.259 15 (9–23) 15 (9–22) 0.040
Number of distinct medications 4 (2–7) 5 (3–8) 0.201 5 (3–8) 5 (3–7) 0.027
Number of hospitalisations 0 (0–1) 0 (0–1) 0.069 0 (0–1) 0 (0–1) 0.059
Number of hospital procedures 0 (0–0) 0 (0–1) 0.093 0 (0–0) 0 (0–0) 0.075




























































































































































































































































































TABLE 15 Characteristics of the mild COPD cohort before and after propensity score matching for the exacerbations analysis (FP-SAL vs. SAL) (CPRD non-interventional population)
Variable

















Age (years), median (IQR) 66 (60–72) 66 (59–73) 0.003 66 (59–72) 66 (59–72) 0.04
Sex (male), n (%) 2104 (54) 2483 (52) 0.047 222 (53) 213 (51) 0.043
Lung function, median (IQR)
FEV1 per cent of predicted 76 (69–87) 76 (67–87) 0.041 74 (67–84) 74 (66–85) 0.043
FEV1 : FVC per cent 68 (61–75) 70 (63–77) 0.143 67 (61–75) 71 (62–78) 0.099
BMI (kg/m2), median (IQR) 28 (25–32) 28 (25–32) 0.055 28 (24–32) 28 (25–32) 0.051
Prior exacerbations, mean (SD) 0.50 (0.87) 0.29 (0.72) 0.263 0.59 (0.98) 0.53 (0.85) 0.055
Cardiovascular disease, n (%)
Coronary heart disease 173 (4) 925 (19) 0.472 52 (12) 43 (10) 0.068
Peripheral vascular disease 52 (1) 256 (5) 0.224 13 (3) 10 (2) 0.044
Cerebrovascular disease 52 (1) 271 (6) 0.237 16 (4) 11 (3) 0.068
Other atherosclerosis 0 (0) 1 (0) 0.02 0 (0) 0 (0) 0.069
Statin prescription, n (%) 1589 (41) 2202 (46) 0.102 169 (41) 151 (36) 0.089
Aspirin prescription, n (%) 1172 (30) 1391 (29) 0.025 119 (29) 112 (27) 0.038
Other COPD medication prescriptions, n (%)
LABA 3455 (89) 36 (1) 3.871 31 (7) 33 (8) 0.018
ICS 1177 (30) 544 (11) 0.481 167 (40) 179 (43) 0.058
LAMA 965 (25) 1795 (38) 0.275 138 (33) 144 (35) 0.03






















































Type 2 diabetes, n (%) 401 (10) 598 (13) 0.068 46 (11) 41 (10) 0.039
History of cancer, n (%) 634 (16) 768 (16) 0.008 69 (17) 60 (14) 0.06
Chronic kidney disease, n (%) 426 (11) 602 (13) 0.049 48 (12) 39 (9) 0.071
Health-care utilisation, median (IQR)
Number of GP consultations 14 (9–21) 16 (10–25) 0.230 15 (10–24) 16 (10–25) 0.059
Number of distinct medications 4 (2–7) 5 (3–8) 0.21 6 (3–8) 6 (3–8) 0.106
Number of hospitalisations 0 (0–1) 0 (0–1) 0.109 0 (0–1) 0 (0–1) 0.125
Number of hospital procedures 0 (0–0) 0 (0–1) 0.093 0 (0–0) 0 (0–0) 0.041





























































































































































































































































































Table 16 shows the results for the association between FP-SAL and COPD exacerbations, mortality and
pneumonia in the patient populations aged > 80 years, those with asthma and those with mild COPD.
Crude associations and associations from propensity score-matched and propensity score-adjusted
analyses are shown.
People aged over 80 years
For the exacerbations analysis, we obtained a propensity score-matched rate ratio of 0.59 (95% CI 0.36
to 0.95) and a propensity score-adjusted rate ratio of 0.83 (95% CI 0.60 to 1.14), which is consistent with
the association measured in the TORCH trial-analogous3 CPRD population (0.85, 95% CI 0.74 to 0.97).
For the mortality outcome, we obtained a propensity score-matched HR of 0.99 (95% CI 0.56 to 1.74)
and a propensity score-adjusted HR of 1.29 (95% CI 0.84 to 2.00), which, again, is consistent with the
TABLE 16 Results for the analysis of exacerbations, mortality and pneumonia comparing FP-SAL with SAL in people in
the CPRD who would not have been eligible for the TORCH trial3 because of (1) being aged > 80 years, (2) having a
diagnosis of asthma within 5 years prior to their start of follow-up or (3) having mild COPD based on lung function
(compared with results for the CPRD TORCH trial-analogous3 cohort)
Analysis
Cohorts of people with COPD in CPRD




Crude rate ratio (95% CI) 1.19 (1.04 to 1.35) 0.71 (0.67 to 0.75) 0.47 (0.44 to 0.51) 0.80 (0.72 to 0.88)
Propensity scored-matched
rate ratio (95% CI)
0.59 (0.36 to 0.95)e 0.74 (0.62 to 0.89)f 0.56 (0.46 to 0.70)g 0.85 (0.74 to 0.97)
Propensity score-adjusted
rate ratio (95% CI)
0.83 (0.60 to 1.14) 0.67 (0.59 to 0.78) 0.52 (0.45 to 0.61) NA
Mortality
Crude HR (95% CI) 0.89 (0.76 to 1.03) 1.07 (0.96 to 1.19) 1.32 (1.06 to 1.64) 1.12 (0.94 to 1.34)
Propensity score-matched
HR (95% CI)
0.99 (0.56 to 1.74)h 1.49 (1.21 to 1.85)i 0.98 (0.67 to 1.45)j 0.93 (0.65 to 1.32)
Propensity score-adjusted
HR (95% CI)
1.29 (0.84 to 2.00) 1.20 (1.04 to 1.40) 0.84 (0.66 to 1.08) NA
Pneumonia
Crude RR (95% CI) 0.97 (0.82 to 1.15) 1.18 (1.05 to 1.32) 1.62 (1.35 to 1.94) 1.35 (1.09 to 1.66)
Propensity score-matched
RR (95% CI)
0.82 (0.44 to 1.53)k 1.09 (0.74 to 1.63)l 0.78 (0.45 to 1.35)m 1.39 (1.04 to 1.87)
Propensity score-adjusted
RR (95% CI)
0.88 (0.54 to 1.42) 1.04 (0.79 to 1.37) 1.08 (0.74 to 1.57) NA
NA, not applicable.
a SAL group, 763 time periods from 194 people; FP-SAL group, 1645 time periods from 670 people.
b SAL group, 5585 time periods from 1175 people; FP-SAL group, 9719 time periods from 3577 people.
c SAL group, 3876 time periods from 877 people; FP-SAL group, 4783 time periods from 2013 people.
d See Table 11 for details of variables included in each of the propensity score models included in this table.
e A total of 84 people per exposure group after matching.
f A total of 554 people per exposure group after matching.
g A total of 434 people per exposure group after matching.
h A total of 94 people per exposure group after matching.
i A total of 910 people per exposure group after matching.
j A total of 1362 people per exposure group after matching.
k A total of 92 people per exposure group after matching.
l A total of 573 people per exposure group after matching.
m A total of 425 people per exposure group after matching.
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TORCH trial-analogous3 CPRD result (0.93, 95% CI 0.65 to 1.32). For the pneumonia analysis, we found
no evidence for an increased risk associated with FP-SAL, with a propensity score-matched rate ratio of
0.82 (95% CI 0.44 to 1.53) and a propensity score-adjusted rate ratio of 0.88 (95% CI 0.54 to 1.42).
People with an asthma diagnosis within 5 years prior to study entry
For the exacerbations analysis, we found a propensity score-matched rate ratio of 0.74 (95% CI 0.62 to
0.89) and a propensity score-adjusted rate ratio of 0.67 (95% CI 0.59 to 0.78), which is consistent with
the association measured in the TORCH trial-analogous3 CPRD population (0.85, 95% CI 0.74 to 0.97).
For the mortality outcome, we obtained a propensity score-matched HR of 1.49 (95% CI 1.21 to 1.85)
and propensity score-adjusted HR of 1.20 (95% CI 1.04 to 1.40), contrary to the null findings with the
TORCH trial-analogous3 CPRD result (0.93, 95% CI 0.65 to 1.32). For the pneumonia analysis, we found
no evidence for an increased risk associated with FP-SAL, with a propensity score-matched rate ratio of
1.09 (95% CI 0.74 to 1.63) and a propensity score-adjusted rate ratio of 1.04 (95% CI 0.79 to 1.37).
People with mild chronic obstructive pulmonary disease (based on spirometry)
For the exacerbations analysis, we found a propensity score-matched rate ratio of 0.56 (95% CI 0.46 to
0.70) and a propensity score-adjusted rate ratio of 0.52 (95% CI 0.45 to 0.61), which suggests a stronger
protective association than that measured in the TORCH trial-analogous3 CPRD population (0.85, 95% CI
0.74 to 0.97). Notably, however, the crude association in those with mild COPD was also strongly
protective, unlike in the TORCH trial-analogous3 population. For the mortality outcome, we obtained a
propensity score-matched HR of 0.98 (95% CI 0.67 to 1.45) and a propensity score-adjusted HR of 0.84
(95% CI 0.66 to 1.08). Again, this is consistent with the TORCH trial-analogous3 CPRD result (0.93, 95% CI
0.65 to 1.32). For the pneumonia analysis, we found no evidence for an increased risk associated with
FP-SAL, with a propensity score-matched rate ratio of 0.78 (95% CI 0.45 to 1.35) and a propensity
score-adjusted rate ratio of 1.08 (95% CI 0.74 to 1.57).
Discussion
In the second part of the project, we applied the observational methods that we previously validated
against the TORCH trial3 to the study of three groups of people who would have been excluded from the
TORCH trial:3 (1) people aged > 80 years, (2) people with a diagnosis of asthma in the preceding 5 years
and (3) people with milder COPD, as determined by lung function. When analysing exacerbations, our
results were consistent with our analysis of the TORCH trial-analogous3 CPRD cohort (and, therefore,
with the TORCH trial3 itself), with the exception of people with milder COPD, for whom we observed a
stronger protective association with FP-SAL. For the analysis of mortality, as for the TORCH trial-analogous3
cohort, we saw a lack of association between being prescribed FP-SAL (vs. being prescribed SAL), with the
exception of those with prior asthma, for whom we observed an increase in mortality. Finally, for the analysis
of pneumonia, although we found an increase in those prescribed FP-SAL in our TORCH trial-analogous3
cohort, we found no evidence of an association in any of our TORCH trial-excluded3 cohorts.
Comparison with previous studies
Previous studies that have extended ‘trial-replication’ approaches to understudied groups
In Comparison with previous studies, we highlighted a number of other studies in which the aim was
to replicate specific trials (and their results).30,32,34 None of these studies specified that further work
was to include the use of the methodology that had been applied to specific study groups excluded
or under-represented in trials. The authors of one of these studies34 (one of whom is a co-investigator
on this grant) are working on the RCT-DUPLICATE (Randomized, Controlled Trials Duplicated Using
Prospective Longitudinal Insurance Claims: Applying Techniques of Epidemiology) project,49 which aims
to use similar trial-replication approaches to those we have used here to determine which types of
clinical questions and real-world data analyses can be conducted with confidence with real-world data.
The work we have performed here contrasts and compliments the RCT-DUPLICATE project,49 as it is
specifically concerned with answering questions about populations that would not be included in trials.
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Previous studies of chronic obstructive pulmonary disease drug treatment effects in groups
excluded from trials
Although it is recognised that treatment of COPD in the elderly population is a particular challenge for
both clinicians and patients,50 there is a lack of studies of treatment effects. Pooled analyses of trial data
have been performed to address this knowledge gap and have demonstrated that effects obtained are
similar to those obtained in overall trial populations.51 In contrast to our methodology, these analyses may
require access to trial data from a large number of trials to achieve sufficient power, rely on the trials being
well performed to produce valid results and can be performed only when these data exist already.52
There is a lack of studies focusing on the effects of COPD treatments on people who have both asthma
and COPD. The ‘recommendations for research’ section of the current NICE guidance on COPD treatment
includes ‘inhaled therapies for people with COPD and asthma’.20 Emerging evidence suggests that this
group of people is a group that is more sick, with higher levels of inflammation and a worse prognosis.53,54
In a recent non-systematic review55 of the evidence for COPD treatment effects in people with mild
COPD, the authors commented on the concerning lack of evidence for commonly used maintenance
treatments (e.g. LABA/ICS combinations) in this population. This review highlights only two studies56,57
that focused on any of the outcomes we studied in mild COPD patients, both focusing on exacerbations
and both only studying monotherapy. The first study was a systematic review and meta-analysis of ICS
compared with placebo and found a lack of effect on exacerbations, although the size of the analysis
was small (n = 191 from three RCTs) and the result had wide CIs (RR 0.92, 95% CI 0.55 to 1.53).56 In the
second study (a RCT), there was no evidence of a difference between exacerbation rate in 391 patients
with mild COPD taking the LABA FP compared with placebo.57
Implications and further work
Our propensity score-matched results for the > 80-year-old cohort suggest that the effect of FP-SAL
(vs. SAL) on exacerbations is of a similar protective magnitude as it is in a cohort of people with similar
characteristics to those in the TORCH trial3 (RR 0.59, 95% CI 0.36 to 0.95 in the > 80-year-old group
compared with RR 0.85, 95% CI 0.74 to 0.97 in our TORCH trial-analogous3 cohort). This provides some
reassurance of the effectiveness of this treatment in this population in a UK primary care setting. Further
work could be to extend this analysis to other drug treatments (e.g. looking at inhaled triple combination
therapy LAMA+ LABA + ICS, as recently added to NICE guidance5) and also assessing whether or not
the same effect is seen when using the same methods applied in a different setting (e.g. an EHR database
from another country). For the mortality and pneumonia effects, although both our propensity score-
matched and our propensity score-adjusted associations were consistent with those found in our TORCH
trial-analogous3 analysis, there were wide CIs. One possibility could be to repeat these analyses and
include the additional EHRs now available in CPRD Aurum.58
For our asthma cohort, the increased mortality observed in the FP-SAL group (in contrast with the null
effect found in our TORCH trial3 analysis) could be a spurious result, possibly due to imbalances in the
cohort that were introduced by our propensity score method (although from Appendix 1, Table 19, the
only observed imbalance introduced to matching is a small difference in FEV1). Further work is, therefore,
needed to investigate this finding. However, as mentioned previously, people with both asthma and COPD
have a poorer prognosis than those with just COPD, and how this has a selective impact on those on
FP-SAL compared with those on SAL while having a protective effect on exacerbations and a null impact
on pneumonia needs further consideration. Future work (in both CPRD GOLD and other data sources)
should focus on identifying any patterns in cause-specific mortality and whether or not this represents
any possible causal association with treatment or unadjusted confounding due to underlying differences
between treatment groups.
Finally, for the cohort of people with mild COPD, our results indicate that there is a stronger
protective effect on exacerbations than those people in the TORCH trial-analogous3 cohort. This is a
potentially reassuring result; however, as it has not been seen before, it would be advisable to try to
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replicate this finding in a completely separate setting using this methodology (e.g. an EHR database
containing a completely distinct population to the CPRD).
Limitations
Some of our analyses had very small numbers. In particular, the propensity score-matched groups for
those aged > 80 years were all < 100 (see Table 11), despite using one of the largest data sets available
for these kinds of analyses. To help address this, we also presented results that were adjusted for the
propensity score rather than matched. Although some of the point estimates differed when comparing
matched with adjusted estimates, none of our conclusions changed for this group when considering the
propensity score-matched cohort with the propensity score-adjusted cohort. Nonetheless, the more recent
availability of even larger quantities of EHR data (i.e. CPRD Aurum) will allow for more precise estimates in
future and would likely mean that any residual discrepancy between matched and adjusted estimates
would be accounted for.
A key limitation of this part of the analysis (that also effects all observational studies) is that we cannot
have the same level of certainty regarding causal associations as would be possible in a well-conducted
randomised trial. Owing to the nature of the research questions in this part of the project, we cannot
know if our results are valid and would replicate those of a reference trial, as for this stage we were
not matching our cohorts to actual trial participants or comparing the results to actual clinical trial
results. However, as discussed in Analysis of impact of (1) TORCH trial3 matching and (2) TORCH trial3
criteria (post hoc analysis), it was the application of the trial inclusion/exclusion criteria when selecting
cohorts that led to trial-comparable results not matching to the individual trial participants, and we
did apply the same rigorous trial selection-type approach (described in Chapter 2, Selection of
participants) to the selection of people for inclusion in all of the cohorts in this section. Furthermore,
our methods for preparing the propensity score models were identical to those used in the TORCH
trial-analogous3 analysis (described in Chapter 2, Propensity score for addressing confounding).
Conclusions
Analyses of the association between FP-SAL and COPD exacerbations, mortality and pneumonia
compared with SAL are largely consistent with the results from the TORCH trial3 when we extend to
patients excluded from or under-represented in the TORCH trial.3 This is largely reassuring, but two
potential differences were noted. First, we observed a larger protective association than expected for
COPD exacerbations in people with mild COPD. Second, and more concerningly, we observed a small
increased risk of death in patients with evidence of both COPD and asthma. Both these signals
warrant further investigation in CPRD GOLD and in other data sets.
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Chapter 4 Overall conclusions
The aims of this project were to measure the association between treatments for COPD and COPDoutcomes among patients not included in RCTs for COPD treatments, and to develop a methodological
framework for using non-interventional EHRs.We have met these aims by completing each of the three
specific primary objectives outlined in Chapter 1, Aims and objectives: (1) validate methods for measuring
COPD medication effectiveness in EHR data by comparing with trial results, (2) use EHR data to measure
COPD medication effectiveness in patients excluded from trials (most importantly, those aged > 80 years
or those with comorbidities) and (3) determine COPD treatment effectiveness in an understudied disease
stage (i.e. mild COPD).
Our results show that routinely collected EHR data can be used to successfully identify the expected
beneficial and harmful effects of treatments for COPD when validating against results obtained from
randomised trials. Importantly, successful replication was possible when comparing between two active
treatments only and could not be achieved for comparisons between active treatment and no treatment.
This was because of (1) confounding by indication (an established challenge when trying to compare with
no treatment) and (2) the fact that the TORCH trial3 placebo-controlled group were such an unhealthy
group in comparison with people with COPD routinely treated in UK primary care (overall much more
recently than the TORCH trial3). These conclusions are specific to investigations of the effects of COPD
medication and cannot be assumed to replicate in other disease areas. In validating against the results of
a large international multicentre randomised trial, it was also clear that, in some instances, some patient
characteristics observed in a trial are not always observed in a single-country EHR setting. This raises
questions of possible trial result heterogeneity by geographic region, which should be considered in
future attempts to replicate trial findings in non-interventional data.
The step of directly comparing findings from non-interventional data with those from the trial provided
a methodological validation and template, allowing further work to focus on the types of patients
excluded from the original trials.
Analyses involving patients who would have been excluded from, or were under-represented in, COPD
treatment trials mostly suggests that treatment effects for FP-SAL are similar in patients aged > 80 years,
those with mild COPD and those with both asthma and COPD. However, some potential differences were
also suggested. For people with mild COPD, the use of FP-SAL appears to be more beneficial with respect
to exacerbations than was seen in the TORCH trial-analogous3 population. By contrast, we observed a
small increased risk of mortality when comparing FP-SAL with SAL in the group with both COPD and
asthma. These associations should be interpreted with caution, and we recommend that future studies
in CPRD GOLD and in other data sets focus on further characterising these associations.
Overall, we have demonstrated the utility of non-interventional data to investigate the expected
treatment effects of COPD medications, in both trial-included and trial-excluded patient groups.
Analyses largely suggest that COPD treatment effects are consistent across different patient groups,
but highlighted a small number of possible differences that need to be investigated further in CPRD
GOLD and other data sets before any conclusions that might have an impact on COPD treatment
decisions can be reached. Unanswered questions about the effectiveness of currently recommended
COPD inhaled combination therapy (other than FP-SAL) in patients excluded from trials should also
be investigated using these methods. In addition, further work on advanced technique (e.g. high-
dimensional propensity scores) could be performed to investigate whether or not placebo-controlled
RCTs can ever be replicated in this therapeutic area (particularly when the target trial is a historical
trial that has recruited patients in the placebo group who are much more sick than patients under
the care of clinicians in a much more recent primary care setting).
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Prioritised list of recommendations for future research
l To further investigate the harmful effect of FP-SAL (vs. SAL) observed with respect to mortality in
people with asthma within the CPRD GOLD data set.
l To update the cohort so that (1) patients can be selected up to January 2020 and (2) patients
can be selected from both CPRD GOLD and CPRD Aurum databases to increase the power of
the subgroup analyses (i.e. for those aged > 80 years, those with mild COPD and those with
concomitant asthma) and to facilitate analysis in those groups that we were unable to analyse
because of small numbers (i.e. people with a history of lung surgery, people with a history of
long-term oxygen therapy, people with substantial comorbidity or people with evidence of
drug/alcohol abuse).
l To apply the methodology developed here to the analysis of other COPD treatments that are of
current interest and relevance to prescribing practice and now specified in NICE guidance, such as
the use of new triple therapy formulations (e.g. LAMA–ICS–LABA) compared with ICS–LABA or
LABA–LAMA formulations.5
l To investigate advanced techniques (e.g. high-dimensional propensity scores) to assess whether or
not it is possible to replicate placebo-controlled outcomes analyses in this therapeutic area when
comparing with historical trials.
OVERALL CONCLUSIONS
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TABLE 17 Characteristics of the aged > 80 years cohort before and after propensity score matching for the mortality analysis (FP-SAL vs. SAL) (CPRD non-interventional population)
Variable
Before propensity score matching After propensity score matching
Exposed to SAL














Age (years), median (IQR) 85 (83–88) 85 (83–88) 0.038 84 (82–87) 85 (82–87) 0.013
Sex (male), n (%) 517 (68) 976 (59) 0.176 49 (66) 40 (54) 0.25
Lung function, median (IQR)
FEV1 per cent of predicted 52 (46–59) 52 (41–59) 0.085 51 (43–57) 46 (37–58) 0.153
FEV1 : FVC per cent 55 (47–63) 55 (45–64) 0.092 52 (47–62) 50 (45–61) 0.294
BMI (kg/m2), median (IQR) 25 (22–28) 25 (22–28) 0.016 25 (23–28) 24 (21–27) 0.233
Prior exacerbations, mean (SD) 0.60 (0.97) 0.73 (1.16) 0.124 0.70 (1.17) 0.99 (1.31) 0.229
Cardiovascular disease, n (%)
Coronary heart disease 55 (7) 391 (24) 0.47 8 (11) 14 (19) 0.229
Peripheral vascular disease 21 (3) 158 (10) 0.288 3 (4) 13 (18) 0.446
Cerebrovascular disease 18 (2) 184 (11) 0.357 3 (4) 7 (9) 0.217
Other atherosclerosis 0 (0) 3 (0) 0.06 0 (0) 0 (0) 0 (0)
Statin prescription, n (%) 328 (43) 694 (42) 0.016 29 (39) 27 (36) 0.056
Aspirin prescription, n (%) 308 (40) 700 (43) 0.044 30 (41) 30 (41) 0.000
Other COPD medication prescriptions, n (%)
LABA 675 (88) 14 (1) 3.728 10 (14) 10 (14) 0.000
ICS 297 (39) 108 (7) 0.837 32 (43) 8 (11) 0.784
LAMA 244 (32) 901 (55) 0.473 29 (39) 44 (59) 0.414
































Before propensity score matching After propensity score matching
Exposed to SAL














Type 2 diabetes, n (%) 103 (13) 195 (12) 0.049 7 (9) 10 (14) 0.127
History of cancer, n (%) 282 (37) 545 (33) 0.08 20 (27) 22 (30) 0.06
Chronic kidney disease, n (%) 223 (29) 675 (41) 0.249 18 (24) 19 (26) 0.031
Health-care utilisation, median (IQR)
Number of GP consultations 49 (35–72) 19 (12–31) 1.161 42 (28–63) 32 (25–57) 0.368
Number of distinct medications 6 (3–9) 6 (3–10) 0.108 6 (3–9) 10 (6–14) 0.827
Number of hospitalisations 0 (0–1) 0 (0–1) 0.106 0 (0–1) 0 (0–1) 0.009
Number of hospital procedures 0 (0–1) 0 (0–2) 0.143 0 (0–1) 0 (0–0) 0.005




























































































































































































































































































TABLE 18 Characteristics of the aged > 80 years cohort before and after propensity score matching for the pneumonia analysis (FP-SAL vs. SAL) (CPRD non-interventional population)
Variable
Before propensity score matching After propensity score matching
Exposed to SAL














Age (years), median (IQR) 85 (83–88) 85 (83–88) 0.038 85 (82–86) 84 (82–87) 0.014
Sex (male), n (%) 517 (68) 976 (59) 0.176 40 (61) 41 (62) 0.031
Lung function, median (IQR)
FEV1 per cent of predicted 52 (46–59) 52 (41–59) 0.085 52 (46–58) 50 (37–59) 0.06
FEV1 : FVC per cent 55 (47–63) 55 (45–64) 0.092 53 (47–63) 52 (44–58) 0.231
BMI (kg/m2), median (IQR) 25 (22–28) 25 (22–28) 0.016 26 (23–28) 24 (22–27) 0.224
Prior exacerbations, mean (SD) 0.60 (0.97) 0.73 (1.16) 0.124 0.86 (1.24) 0.76 (1.02) 0.093
Cardiovascular disease, n (%)
Coronary heart disease 55 (7) 391 (24) 0.47 10 (15) 16 (24) 0.23
Peripheral vascular disease 21 (3) 158 (10) 0.288 3 (5) 10 (15) 0.362
Cerebrovascular disease 18 (2) 184 (11) 0.357 3 (5) 6 (9) 0.181
Other atherosclerosis 0 (0) 3 (0) 0.06 0 (0) 0 (0) 0 (0)
Statin prescription, n (%) 328 (43) 694 (42) 0.016 24 (36) 31 (47) 0.216
Aspirin prescription, n (%) 308 (40) 700 (43) 0.044 28 (42) 29 (44) 0.031
Other COPD medication prescriptions, n (%)
LABA 675 (88) 14 (1) 3.728 10 (15) 10 (15) 0.000
ICS 297 (39) 108 (7) 0.837 28 (42) 4 (6) 0.937
LAMA 244 (32) 901 (55) 0.473 29 (44) 40 (61) 0.338
































Before propensity score matching After propensity score matching
Exposed to SAL














Type 2 diabetes, n (%) 103 (13) 195 (12) 0.049 7 (11) 13 (20) 0.256
History of cancer, n (%) 282 (37) 545 (33) 0.08 17 (26) 33 (50) 0.516
Chronic kidney disease, n (%) 223 (29) 675 (41) 0.249 20 (30) 13 (20) 0.247
Health-care utilisation, median (IQR)
Number of GP consultations 49 (35–72) 19 (12–31) 1.161 43 (28–81) 34 (25–53) 0.568
Number of distinct medications 6 (3–9) 6 (3–10) 0.108 7 (4–10) 7 (5–13) 0.271
Number of hospitalisations 0 (0–1) 0 (0–1) 0.106 0 (0–1) 0 (0–1) 0.178
Number of hospital procedures 0 (0–1) 0 (0–2) 0.143 0 (0–1) 0 (0–2) 0.066




























































































































































































































































































TABLE 19 Characteristics of the cohort with an asthma diagnosis during the previous 5 years before and after propensity score matching for the mortality analysis (FP-SAL vs. SAL)
(CPRD non-interventional population)
Variable
Before propensity score matching After propensity score matching
Exposed to SAL














Age (years), median (IQR) 68 (61–73) 66 (59–72) 0.192 68 (61–73) 68 (61–74) 0.028
Sex (male), n (%) 2923 (52) 5409 (56) 0.067 1021 (52) 1050 (53) 0.029
Lung function, median (IQR)
FEV1 per cent of predicted 53 (42–62) 52 (41–61) 0.031 54 (44–63) 50 (40–59) 0.198
FEV1 : FVC per cent 55 (45–63) 55 (46–63) 0.022 54 (45–63) 54 (45–63) 0.032
BMI (kg/m2), median (IQR) 27 (24–31) 27 (24–32) 0.106 27 (24–31) 27 (23–31) 0.035
Prior exacerbations, mean (SD) 0.62 (1.02) 0.48 (1.01) 0.14 0.49 (0.93) 0.56 (1.07) 0.078
Cardiovascular disease, n (%)
Coronary heart disease 190 (3) 268 (3) 0.037 65 (3) 51 (3) 0.042
Peripheral vascular disease 60 (1) 60 (1) 0.05 19 (1) 16 (1) 0.016
Cerebrovascular disease 73 (1) 163 (2) 0.031 27 (1) 28 (1) 0.004
Other atherosclerosis 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Statin prescription, n (%) 2141 (38) 3742 (39) 0.003 785 (40) 774 (39) 0.011
Aspirin prescription, n (%) 1281 (23) 2401 (25) 0.042 506 (26) 493 (25) 0.015
Other COPD medication prescriptions, n (%)
LABA 5123 (92) 172 (2) 4.166 1787 (91) 89 (5) 3.389
ICS 4177 (75) 1071 (11) 1.685 631 (32) 662 (34) 0.033
LAMA 1630 (29) 5193 (53) 0.508 865 (44) 865 (44) 0.000
































Before propensity score matching After propensity score matching
Exposed to SAL














Type 2 diabetes, n (%) 718 (13) 1429 (15) 0.054 283 (14) 263 (13) 0.029
History of cancer, n (%) 980 (18) 1629 (17) 0.021 362 (18) 353 (18) 0.012
Chronic kidney disease, n (%) 579 (10) 1142 (12) 0.044 221 (11) 245 (12) 0.038
Health-care utilisation, median (IQR)
Number of GP consultations 13 (8–21) 16 (9–26) 0.259 15 (9–24) 15 (10–24) 0.036
Number of distinct medications 4 (2–7) 5 (3–8) 0.201 5 (3–7) 5 (3–8) 0.076
Number of hospitalisations 0 (0–1) 0 (0–1) 0.069 0 (0–1) 0 (0–1) 0.008
Number of hospital procedures 0 (0–0) 0 (0–1) 0.093 0 (0–0) 0 (0–0) 0.003




























































































































































































































































































TABLE 20 Characteristics of the cohort with an asthma diagnosis during the previous 5 years before and after propensity score matching for the pneumonia analysis (FP-SAL vs. SAL)
(CPRD non-interventional population)
Variable
Before propensity score matching After propensity score matching
Exposed to SAL














Age (years), median (IQR) 68 (61–73) 66 (59–72) 0.192 68 (62–73) 68 (61–74) 0.022
Sex (male), n (%) 2923 (52) 5409 (56) 0.067 294 (52) 316 (56) 0.078
Lung function, median (IQR)
FEV1 per cent of predicted 53 (42–62) 52 (41–61) 0.031 52 (41–61) 51 (39–60) 0.055
FEV1 : FVC per cent 55 (45–63) 55 (46–63) 0.022 54 (46–63) 54 (45–63) 0.019
BMI (kg/m2), median (IQR) 27 (24–31) 27 (24–32) 0.106 27 (24–31) 27 (24–30) 0.106
Prior exacerbations, mean (SD) 0.62 (1.02) 0.48 (1.01) 0.14 0.64 (1.05) 0.73 (1.11) 0.085
Cardiovascular disease, n (%)
Coronary heart disease 190 (3) 268 (3) 0.037 30 (5) 34 (6) 0.031
Peripheral vascular disease 60 (1) 60 (1) 0.05 10 (2) 10 (2) 0.000
Cerebrovascular disease 73 (1) 163 (2) 0.031 14 (2) 9 (2) 0.063
Other atherosclerosis 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Statin prescription, n (%) 2141 (38) 3742 (39) 0.003 195 (35) 195 (35) 0.000
Aspirin prescription, n (%) 1281 (23) 2401 (25) 0.042 136 (24) 126 (22) 0.042
Other COPD medication prescriptions, n (%)
LABA 5123 (92) 172 (2) 4.166 124 (22) 127 (23) 0.013
ICS 4177 (75) 1071 (11) 1.685 366 (65) 166 (29) 0.76
LAMA 1630 (29) 5193 (53) 0.508 215 (38) 193 (34) 0.081
































Before propensity score matching After propensity score matching
Exposed to SAL














Type 2 diabetes, n (%) 718 (13) 1429 (15) 0.054 69 (12) 61 (11) 0.044
History of cancer, n (%) 980 (18) 1629 (17) 0.021 102 (18) 97 (17) 0.023
Chronic kidney disease, n (%) 579 (10) 1142 (12) 0.044 52 (9) 49 (9) 0.019
Health-care utilisation, median (IQR)
Number of GP consultations 13 (8–21) 16 (9–26) 0.259 15 (9–23) 14 (9–21) 0.066
Number of distinct medications 4 (2–7) 5 (3–8) 0.201 5 (3–8) 5 (3–8) 0.015
Number of hospitalisations 0 (0–1) 0 (0–1) 0.069 0 (0–1) 0 (0–0) 0.077
Number of hospital procedures 0 (0–0) 0 (0–1) 0.093 0 (0–0) 0 (0–0) 0.118




























































































































































































































































































TABLE 21 Characteristics of the mild COPD cohort before and after propensity score matching for the mortality analysis (FP-SAL vs. SAL) (CPRD non-interventional population)
Variable

















Age (years), median (IQR) 66 (60–72) 66 (59–73) 0.003 65 (58–71) 66 (59–72) 0.099
Sex (male), n (%) 2104 (54) 2483 (52) 0.047 656 (48) 714 (52) 0.085
Lung function, median (IQR)
FEV1 per cent of predicted 76 (69–87) 76 (67–87) 0.041 76 (69–86) 75 (66–87) 0.091
FEV1 : FVC per cent 68 (61–75) 70 (63–77) 0.143 68 (61–74) 69 (62–77) 0.124
BMI (kg/m2), median (IQR) 28 (25–32) 28 (25–32) 0.055 28 (24–32) 28 (24–32) 0.019
Prior exacerbations, mean (SD) 0.50 (0.87) 0.29 (0.72) 0.263 0.26 (0.69) 0.30 (0.71) 0.061
Cardiovascular disease, n (%)
Coronary heart disease 173 (4) 925 (19) 0.472 157 (12) 143 (10) 0.033
Peripheral vascular disease 52 (1) 256 (5) 0.224 48 (4) 43 (3) 0.02
Cerebrovascular disease 52 (1) 271 (6) 0.237 49 (4) 38 (3) 0.046
Other atherosclerosis 0 (0) 1 (0) 0.02 0 (0) 0 (0) 0.038
Statin prescription, n (%) 1589 (41) 2202 (46) 0.102 476 (35) 530 (39) 0.082
Aspirin prescription, n (%) 1172 (30) 1391 (29) 0.025 279 (20) 325 (24) 0.081
Other COPD medication prescriptions, n (%)
LABA 3455 (89) 36 (1) 3.871 1197 (88) 16 (1) 3.569
ICS 1177 (30) 544 (11) 0.481 158 (12) 233 (17) 0.158
LAMA 965 (25) 1795 (38) 0.275 456 (33) 482 (35) 0.04

















































Type 2 diabetes, n (%) 401 (10) 598 (13) 0.068 132 (10) 152 (11) 0.048
History of cancer, n (%) 634 (16) 768 (16) 0.008 180 (13) 230 (17) 0.103
Chronic kidney disease, n (%) 426 (11) 602 (13) 0.049 119 (9) 147 (11) 0.069
Health-care utilisation, median (IQR)
Number of GP consultations 14 (9–21) 16 (10–25) 0.230 15 (10–23) 16 (10–25) 0.082
Number of distinct medications 4 (2–7) 5 (3–8) 0.21 5 (3–8) 5 (3–8) 0.172
Number of hospitalisations 0 (0–1) 0 (0–1) 0.109 0 (0–1) 0 (0–1) 0.081
Number of hospital procedures 0 (0–0) 0 (0–1) 0.093 0 (0–0) 0 (0–0) 0.062




























































































































































































































































































TABLE 22 Characteristics of the mild COPD cohort before and after propensity score matching for the pneumonia analysis (FP-SAL vs. SAL) (CPRD non-interventional population)
Variable

















Age (years), median (IQR) 66 (60–72) 66 (59–73) 0.003 66 (59–73) 66 (59–72) 0.038
Sex (male), n (%) 2104 (54) 2483 (52) 0.047 217 (51) 222 (52) 0.024
Lung function, median (IQR)
FEV1 per cent of predicted 76 (69–87) 76 (67–87) 0.041 74 (67–84) 75 (66–86) 0.017
FEV1 : FVC per cent 68 (61–75) 70 (63–77) 0.143 67 (61–75) 71 (63–78) 0.171
BMI (kg/m2), median (IQR) 28 (25–32) 28 (25–32) 0.055 28 (24–32) 27 (24–31) 0.022
Prior exacerbations, mean (SD) 0.50 (0.87) 0.29 (0.72) 0.263 0.59 (0.97) 0.56 (0.90) 0.033
Cardiovascular disease, n (%)
Coronary heart disease 173 (4) 925 (19) 0.472 56 (13) 41 (10) 0.111
Peripheral vascular disease 52 (1) 256 (5) 0.224 12 (3) 8 (2) 0.062
Cerebrovascular disease 52 (1) 271 (6) 0.237 15 (4) 11 (3) 0.055
Other atherosclerosis 0 (0) 1 (0) 0.02 0 (0) 0 (0) 0.069
Statin prescription, n (%) 1589 (41) 2202 (46) 0.102 173 (41) 158 (37) 0.072
Aspirin prescription, n (%) 1172 (30) 1391 (29) 0.025 122 (29) 121 (28) 0.005
Other COPD medication prescriptions, n (%)
LABA 3455 (89) 36 (1) 3.871 31 (7) 31 (7) 0.000
ICS 1177 (30) 544 (11) 0.481 187 (44) 92 (22) 0.490
LAMA 965 (25) 1795 (38) 0.275 137 (32) 142 (33) 0.025

















































Type 2 diabetes, n (%) 401 (10) 598 (13) 0.068 49 (12) 40 (9) 0.069
History of cancer, n (%) 634 (16) 768 (16) 0.008 68 (16) 63 (15) 0.033
Chronic kidney disease, n (%) 426 (11) 602 (13) 0.049 49 (12) 46 (11) 0.022
Healthcare utilisation, median (IQR)
Number of GP consultations 14 (9–21) 16 (10–25) 0.230 15 (10–24) 16 (10–24) 0.011
Number of distinct medications 4 (2–7) 5 (3–8) 0.21 5 (3–8) 5 (3–8) 0.037
Number of hospitalisations 0 (0–1) 0 (0–1) 0.109 0 (0–1) 0 (0–1) 0.073
Number of hospital procedures 0 (0–0) 0 (0–1) 0.093 0 (0–0) 0 (0–0) 0.087
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